Therapeutic Targeting the Allosteric Cysteinome of RAS and Kinase Families
[Display omitted] •Allosteric inhibitors have many theoretical advantages including superior selectivity, the ability to modulate allosteric biological processes, and the ability to fine-tune biological responses.•Allosteric KRAS G12C inhibitor development showed that covalent chemistry can convert...
Saved in:
| Published in | Journal of molecular biology Vol. 434; no. 17; p. 167626 |
|---|---|
| Main Authors | , , , , |
| Format | Journal Article |
| Language | English |
| Published |
Netherlands
Elsevier Ltd
15.09.2022
|
| Subjects | |
| Online Access | Get full text |
Cover
Loading…
| Abstract | [Display omitted]
•Allosteric inhibitors have many theoretical advantages including superior selectivity, the ability to modulate allosteric biological processes, and the ability to fine-tune biological responses.•Allosteric KRAS G12C inhibitor development showed that covalent chemistry can convert a suboptimal binding pocket into a druggable pocket.•In this review, we review the broader history of allosteric inhibitor development in the RAS and kinase fields and identify opportunities to accelerate allosteric drug development by leveraging covalent chemistry targeting cysteines.
Allosteric mechanisms are pervasive in nature, but human-designed allosteric perturbagens are rare. The history of KRASG12C inhibitor development suggests that covalent chemistry may be a key to expanding the armamentarium of allosteric inhibitors. In that effort, irreversible targeting of a cysteine converted a non-deal allosteric binding pocket and low affinity ligands into a tractable drugging strategy. Here we examine the feasibility of expanding this approach to other allosteric pockets of RAS and kinase family members, given that both protein families are regulators of vital cellular processes that are often dysregulated in cancer and other human diseases. Moreover, these heavily studied families are the subject of numerous drug development campaigns that have resulted, sometimes serendipitously, in the discovery of allosteric inhibitors. We consequently conducted a comprehensive search for cysteines, a commonly targeted amino acid for covalent drugs, using AlphaFold-generated structures of those families. This new analysis presents potential opportunities for allosteric targeting of validated and understudied drug targets, with an emphasis on cancer therapy. |
|---|---|
| AbstractList | Allosteric mechanisms are pervasive in nature, but human-designed allosteric perturbagens are rare. The history of KRASG12C inhibitor development suggests that covalent chemistry may be a key to expanding the armamentarium of allosteric inhibitors. In that effort, irreversible targeting of a cysteine converted a non-deal allosteric binding pocket and low affinity ligands into a tractable drugging strategy. Here we examine the feasibility of expanding this approach to other allosteric pockets of RAS and kinase family members, given that both protein families are regulators of vital cellular processes that are often dysregulated in cancer and other human diseases. Moreover, these heavily studied families are the subject of numerous drug development campaigns that have resulted, sometimes serendipitously, in the discovery of allosteric inhibitors. We consequently conducted a comprehensive search for cysteines, a commonly targeted amino acid for covalent drugs, using AlphaFold-generated structures of those families. This new analysis presents potential opportunities for allosteric targeting of validated and understudied drug targets, with an emphasis on cancer therapy.Allosteric mechanisms are pervasive in nature, but human-designed allosteric perturbagens are rare. The history of KRASG12C inhibitor development suggests that covalent chemistry may be a key to expanding the armamentarium of allosteric inhibitors. In that effort, irreversible targeting of a cysteine converted a non-deal allosteric binding pocket and low affinity ligands into a tractable drugging strategy. Here we examine the feasibility of expanding this approach to other allosteric pockets of RAS and kinase family members, given that both protein families are regulators of vital cellular processes that are often dysregulated in cancer and other human diseases. Moreover, these heavily studied families are the subject of numerous drug development campaigns that have resulted, sometimes serendipitously, in the discovery of allosteric inhibitors. We consequently conducted a comprehensive search for cysteines, a commonly targeted amino acid for covalent drugs, using AlphaFold-generated structures of those families. This new analysis presents potential opportunities for allosteric targeting of validated and understudied drug targets, with an emphasis on cancer therapy. Allosteric mechanisms are pervasive in nature, but human-designed allosteric perturbagens are rare. The history of KRASᴳ¹²C inhibitor development suggests that covalent chemistry may be a key to expanding the armamentarium of allosteric inhibitors. In that effort, irreversible targeting of a cysteine converted a non-deal allosteric binding pocket and low affinity ligands into a tractable drugging strategy. Here we examine the feasibility of expanding this approach to other allosteric pockets of RAS and kinase family members, given that both protein families are regulators of vital cellular processes that are often dysregulated in cancer and other human diseases. Moreover, these heavily studied families are the subject of numerous drug development campaigns that have resulted, sometimes serendipitously, in the discovery of allosteric inhibitors. We consequently conducted a comprehensive search for cysteines, a commonly targeted amino acid for covalent drugs, using AlphaFold-generated structures of those families. This new analysis presents potential opportunities for allosteric targeting of validated and understudied drug targets, with an emphasis on cancer therapy. Allosteric mechanisms are pervasive in nature, but human-designed allosteric perturbagens are rare. The history of KRAS inhibitor development suggests that covalent chemistry may be a key to expanding the armamentarium of allosteric inhibitors. In that effort, irreversible targeting of a cysteine converted a non-deal allosteric binding pocket and low affinity ligands into a tractable drugging strategy. Here we examine the feasibility of expanding this approach to other allosteric pockets of RAS and kinase family members, given that both protein families are regulators of vital cellular processes that are often dysregulated in cancer and other human diseases. Moreover, these heavily studied families are the subject of numerous drug development campaigns that have resulted, sometimes serendipitously, in the discovery of allosteric inhibitors. We consequently conducted a comprehensive search for cysteines, a commonly targeted amino acid for covalent drugs, using AlphaFold-generated structures of those families. This new analysis presents potential opportunities for allosteric targeting of validated and understudied drug targets, with an emphasis on cancer therapy. Allosteric mechanisms are pervasive in nature, but human-designed allosteric perturbagens are rare. The history of KRAS G12C inhibitor development suggests that covalent chemistry may be a key to expanding the armamentarium of allosteric inhibitors. In that effort, irreversible targeting of a cysteine converted a non-deal allosteric binding pocket and low affinity ligands into a tractable drugging strategy. Here we examine the feasibility of expanding this approach to other allosteric pockets of RAS and kinase family members, given that both protein families are regulators of vital cellular processes that are often dysregulated in cancer and other human diseases. Moreover, these heavily studied families are the subject of numerous drug development campaigns that have resulted, sometimes serendipitously, in the discovery of allosteric inhibitors. We consequently conducted a comprehensive search for cysteines, a commonly targeted amino acid for covalent drugs, using AlphaFold-generated structures of those families. This new analysis presents potential opportunities for allosteric targeting of validated and understudied drug targets, with an emphasis on cancer therapy. [Display omitted] •Allosteric inhibitors have many theoretical advantages including superior selectivity, the ability to modulate allosteric biological processes, and the ability to fine-tune biological responses.•Allosteric KRAS G12C inhibitor development showed that covalent chemistry can convert a suboptimal binding pocket into a druggable pocket.•In this review, we review the broader history of allosteric inhibitor development in the RAS and kinase fields and identify opportunities to accelerate allosteric drug development by leveraging covalent chemistry targeting cysteines. Allosteric mechanisms are pervasive in nature, but human-designed allosteric perturbagens are rare. The history of KRASG12C inhibitor development suggests that covalent chemistry may be a key to expanding the armamentarium of allosteric inhibitors. In that effort, irreversible targeting of a cysteine converted a non-deal allosteric binding pocket and low affinity ligands into a tractable drugging strategy. Here we examine the feasibility of expanding this approach to other allosteric pockets of RAS and kinase family members, given that both protein families are regulators of vital cellular processes that are often dysregulated in cancer and other human diseases. Moreover, these heavily studied families are the subject of numerous drug development campaigns that have resulted, sometimes serendipitously, in the discovery of allosteric inhibitors. We consequently conducted a comprehensive search for cysteines, a commonly targeted amino acid for covalent drugs, using AlphaFold-generated structures of those families. This new analysis presents potential opportunities for allosteric targeting of validated and understudied drug targets, with an emphasis on cancer therapy. |
| ArticleNumber | 167626 |
| Author | Meyer, Cynthia Elmezayen, Ammar Zhou, Zhi-Wei Li, Lianbo Westover, Kenneth |
| Author_xml | – sequence: 1 givenname: Lianbo surname: Li fullname: Li, Lianbo – sequence: 2 givenname: Cynthia surname: Meyer fullname: Meyer, Cynthia – sequence: 3 givenname: Zhi-Wei surname: Zhou fullname: Zhou, Zhi-Wei – sequence: 4 givenname: Ammar surname: Elmezayen fullname: Elmezayen, Ammar – sequence: 5 givenname: Kenneth surname: Westover fullname: Westover, Kenneth email: Kenneth.westover@utsouthwestern.edu |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/35595166$$D View this record in MEDLINE/PubMed |
| BookMark | eNqFkV9rFDEUxYNU7Lb6AXyRefRl1vybOwmCsCxWrYWCrs8hnbnZzTKTrEm20G_vLFuL9qF9uhfO7xxucs7ISYgBCXnL6JxRBh-28-14M-eU8zmDFji8IDNGla4VCHVCZnRSaq4EnJKznLeU0kZI9YqciqbRDQOYkcvVBpPd4b74rlrZtMbiw7oqG6wWwxBzwTQJy7tp8SGOWEVX_Vj8rGzoq-8-2IzVhR394DG_Ji-dHTK-uZ_n5NfF59Xya311_eXbcnFVd1LJUiOAcw1IxhvpQFkUvdKICLRRVkvtWooSVENBaSqdRWZ7q22vnLACuBTn5NMxd7e_GbHvMJRkB7NLfrTpzkTrzf9K8BuzjrdGN5oKKqaA9_cBKf7eYy5m9LnDYbAB4z4b3jLFhWwlex4FaFsFUusJfffvWQ_3_P3rCWBHoEsx54TuAWHUHPo0WzP1aQ59mmOfk6d95Ol8scXHw8v88KTz49GJUxW3HpPJncfQYe8TdsX00T_h_gMMVrmE |
| CitedBy_id | crossref_primary_10_1016_j_slasd_2024_100198 crossref_primary_10_1080_17460441_2024_2387856 crossref_primary_10_3390_molecules27175710 crossref_primary_10_59761_RCR5107 crossref_primary_10_1016_j_bbadis_2025_167680 crossref_primary_10_1016_j_bcp_2024_116405 crossref_primary_10_1016_j_jmb_2022_167751 crossref_primary_10_1021_acs_jpcb_2c04346 |
| Cites_doi | 10.1158/1535-7163.MCT-13-0164 10.1038/nchembio.162 10.1016/j.bmcl.2013.01.047 10.1038/s41594-018-0061-5 10.1021/acschembio.7b00980 10.1038/s41586-019-1694-1 10.1038/nature21702 10.1038/35077225 10.1126/scisignal.2004021 10.1073/pnas.1102376108 10.1038/s41573-021-00252-y 10.1016/j.pep.2006.06.005 10.1038/nchembio760 10.1038/s41594-021-00667-6 10.1182/blood.V90.9.3691 10.1038/nature17960 10.1074/jbc.M111.334524 10.1200/JCO.2017.74.7576 10.2174/138161212800672813 10.1021/bi9805691 10.1038/ng.3984 10.1074/jbc.RA119.009131 10.1016/0092-8674(90)90801-K 10.1083/jcb.111.1.143 10.1038/nature14405 10.1073/pnas.1918164117 10.1021/acs.jmedchem.8b00280 10.1073/pnas.1904529116 10.1016/j.cell.2013.03.034 10.1002/iub.393 10.1016/S0092-8674(03)00191-0 10.1038/s41568-021-00340-6 10.1016/j.phrs.2021.106037 10.1016/j.bmcl.2008.12.076 10.1016/j.eclinm.2021.101185 10.1074/jbc.M112.435941 10.1021/acs.jmedchem.6b00680 10.1002/prot.20232 10.1038/292506a0 10.1038/nsmb859 10.1093/emboj/19.5.979 10.1002/anie.201707630 10.1021/cb1002619 10.1080/13543784.2019.1657825 10.1038/s41467-021-21273-6 10.1126/science.1075762 10.1038/35036052 10.1038/2041104b0 10.1002/anie.201307387 10.1016/S0092-8674(02)00741-9 10.1039/C9CS00720B 10.1056/NEJMoa1917239 10.1039/D0MD00154F 10.1146/annurev-biochem-090308-173656 10.4155/fmc-2020-0236 10.1158/0008-5472.CAN-11-2612 10.1038/s41586-018-0201-4 10.1371/journal.pone.0015929 10.3389/fphys.2019.00148 10.1038/nature08675 10.1073/pnas.1116051110 10.1042/BJ20150251 10.1093/annonc/mdv072 10.1158/2159-8290.CD-15-1105 10.1093/nar/gkj067 10.1016/S0968-0896(97)00021-7 10.1016/S1470-2045(12)70270-X 10.1002/anie.201201358 10.1016/0968-0004(91)90134-H 10.1016/j.chembiol.2012.05.009 10.1021/cr500495x 10.1158/2159-8290.CD-18-1220 10.1016/S0968-0896(96)00202-7 10.1016/j.str.2004.02.005 10.1038/375554a0 10.1038/nature18621 10.1021/acs.biochem.7b00974 10.1021/ml100044h 10.1126/science.aad6204 10.1038/s41467-018-04941-y 10.1021/ml500242y 10.1021/acsmedchemlett.6b00373 10.1073/pnas.0307512101 10.1038/nrm2476 10.1126/science.2406906 10.1002/bdr2.1647 10.1073/pnas.1415365112 10.1517/14728222.2013.828037 10.1111/bph.13096 10.1016/j.chembiol.2012.12.006 10.1038/nature12796 10.1016/0092-8674(90)90018-A 10.1146/annurev.biochem.69.1.373 10.1002/cmdc.201900107 10.1126/science.277.5324.333 10.1074/jbc.273.33.20685 10.1016/j.dib.2015.10.001 10.1038/nchembio751 10.1016/S1556-0864(21)01941-9 10.1038/s41586-019-1923-7 10.1007/s00018-019-03208-z 10.1126/science.1084073 10.1021/acs.accounts.8b00570 10.1021/acsmedchemlett.5b00102 10.1038/nature13001 10.1021/jm901297e 10.1038/s41573-020-0068-6 10.1111/dom.13338 10.1016/j.cclet.2010.07.023 10.1002/j.1460-2075.1984.tb02177.x 10.1073/pnas.1404639111 10.1021/jm300276x 10.1158/1541-7786.MCR-15-0203 10.1021/cb3005879 10.1074/jbc.272.22.14459 10.1002/anie.201914525 10.2174/156802612804547407 10.1038/228726a0 10.1080/17460441.2022.2034783 10.1016/j.ccr.2014.02.017 |
| ContentType | Journal Article |
| Copyright | 2022 Elsevier Ltd Copyright © 2022 Elsevier Ltd. All rights reserved. |
| Copyright_xml | – notice: 2022 Elsevier Ltd – notice: Copyright © 2022 Elsevier Ltd. All rights reserved. |
| DBID | AAYXX CITATION NPM 7X8 7S9 L.6 5PM |
| DOI | 10.1016/j.jmb.2022.167626 |
| DatabaseName | CrossRef PubMed MEDLINE - Academic AGRICOLA AGRICOLA - Academic PubMed Central (Full Participant titles) |
| DatabaseTitle | CrossRef PubMed MEDLINE - Academic AGRICOLA AGRICOLA - Academic |
| DatabaseTitleList | MEDLINE - Academic AGRICOLA PubMed |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Chemistry Biology |
| EISSN | 1089-8638 |
| EndPage | 167626 |
| ExternalDocumentID | PMC9590303 35595166 10_1016_j_jmb_2022_167626 S0022283622002066 |
| Genre | Journal Article Review |
| GroupedDBID | --- --K --M -DZ -ET -~X .~1 0R~ 1B1 1RT 1~. 1~5 4.4 457 4G. 53G 5GY 5RE 5VS 7-5 71M 85S 8P~ 9JM AAAJQ AABNK AACTN AAEDT AAEDW AAHBH AAIKJ AAKOC AALRI AAOAW AAQFI AARKO AATTM AAXKI AAXUO ABFNM ABFRF ABGSF ABJNI ABLJU ABMAC ABOCM ABPPZ ABUDA ACDAQ ACGFO ACGFS ACNCT ACRLP ADBBV ADEZE ADUVX ADVLN AEBSH AEFWE AEHWI AEIPS AEKER AENEX AFFNX AFTJW AFXIZ AGEKW AGUBO AGYEJ AHHHB AIEXJ AIKHN AITUG AKRWK ALMA_UNASSIGNED_HOLDINGS AMRAJ ANKPU AXJTR BKOJK BLXMC BNPGV CJTIS CS3 DM4 DU5 EBS EFBJH EO8 EO9 EP2 EP3 F5P FDB FIRID FNPLU FYGXN G-Q GBLVA GX1 HMG IH2 IHE J1W KOM LG5 LUGTX LX2 LZ5 M41 MO0 N9A O-L O9- OAUVE OZT P-8 P-9 P2P PC. Q38 RNS ROL RPZ SDF SDG SDP SES SPCBC SSH SSI SSU SSZ T5K TWZ WH7 XPP YQT ZMT ZU3 ~G- .55 .GJ 186 29L 3O- AAQXK AAYWO AAYXX ABDPE ABEFU ABWVN ABXDB ACKIV ACRPL ACVFH ADCNI ADFGL ADIYS ADMUD ADNMO ADXHL AEUPX AFJKZ AFPUW AGCQF AGHFR AGQPQ AGRDE AGRNS AI. AIGII AIIUN AKBMS AKYEP APXCP ASPBG AVWKF AZFZN CAG CITATION COF EJD FEDTE FGOYB G-2 HLW HVGLF HX~ HZ~ H~9 K-O MVM NEJ R2- RIG SBG SEW SIN UQL VH1 WUQ X7M XJT XOL Y6R YYP ZGI ZKB ~KM NPM 7X8 7S9 EFKBS L.6 5PM |
| ID | FETCH-LOGICAL-c484t-e66ff5641254f68ae3d89eee6058a949f70e4685068904fae1ada9ad8f3a36243 |
| IEDL.DBID | .~1 |
| ISSN | 0022-2836 1089-8638 |
| IngestDate | Thu Aug 21 18:39:23 EDT 2025 Mon Jul 21 09:49:00 EDT 2025 Fri Jul 11 16:24:41 EDT 2025 Thu Apr 03 07:08:31 EDT 2025 Tue Jul 01 03:50:37 EDT 2025 Thu Apr 24 23:03:01 EDT 2025 Sun Apr 06 06:56:15 EDT 2025 |
| IsDoiOpenAccess | false |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 17 |
| Keywords | kinase inhibitor cysteinome allosteric inhibitor KRAS inhibitor covalent inhibitor |
| Language | English |
| License | Copyright © 2022 Elsevier Ltd. All rights reserved. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c484t-e66ff5641254f68ae3d89eee6058a949f70e4685068904fae1ada9ad8f3a36243 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 ObjectType-Review-3 content type line 23 |
| OpenAccessLink | https://www.ncbi.nlm.nih.gov/pmc/articles/9590303 |
| PMID | 35595166 |
| PQID | 2667786499 |
| PQPubID | 23479 |
| PageCount | 1 |
| ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_9590303 proquest_miscellaneous_2718234741 proquest_miscellaneous_2667786499 pubmed_primary_35595166 crossref_primary_10_1016_j_jmb_2022_167626 crossref_citationtrail_10_1016_j_jmb_2022_167626 elsevier_sciencedirect_doi_10_1016_j_jmb_2022_167626 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2022-09-15 |
| PublicationDateYYYYMMDD | 2022-09-15 |
| PublicationDate_xml | – month: 09 year: 2022 text: 2022-09-15 day: 15 |
| PublicationDecade | 2020 |
| PublicationPlace | Netherlands |
| PublicationPlace_xml | – name: Netherlands |
| PublicationTitle | Journal of molecular biology |
| PublicationTitleAlternate | J Mol Biol |
| PublicationYear | 2022 |
| Publisher | Elsevier Ltd |
| Publisher_xml | – name: Elsevier Ltd |
| References | Liu, Du, Yao, Wei, Zhu, Cui (b0115) 2021; 42 Kessler, Gmachl, Mantoulidis, Martin, Zoephel, Mayer (b0410) 2019; 116 Sutanto, Konstantinidou, Dömling (b0650) 2020; 11 Lu, Hunter, Manandhar, Gurbani, Westover (b0220) 2015; 5 Lim, Westover, Ficarro, Harrison, Choi, Pacold (b0390) 2014; 53 R. Janssen, Development LLC. First-in-Human Study of JNJ-74699157 in Participants With Tumors Harboring the KRAS G12C Mutation, 2020. Simons, Toomre (b0425) 2000; 1 Hunkeler, Hagmann, Stuttfeld, Chami, Guri, Stahlberg (b0165) 2018; 558 Tsherniak, Vazquez, Montgomery, Weir, Kryukov, Cowley (b0675) 2017; 170 Hong, Kenney, Phillips, Simpson, Schroeder, Noth (b0700) 2013; 288 University of V. Effects of Modulators of Gluconeogenesis, Glycogenolysis and Glucokinase Activity, 2022. Gunasekaran, Ma, Nussinov (b0065) 2004; 57 Ellis, Defeo, Shih, Gonda, Young, Tsuchida (b0195) 1981; 292 Ullrich, Schlessinger (b0420) 1990; 61 Riely, Ou, Rybkin, Spira, Papadopoulos, Sabari (b0280) 2021; 16 I. Revolution Medicines, Sanofi, Amgen, Combination Study of RMC-4630 and Sotorasib for NSCLC Subjects With KRASG12C Mutation After Failure of Prior Standard Therapies, 2023. Bera, Lu, Lu, Li, Gondi, Yan (b0235) 2020; 112 Goody, Frech, Wittinghofer (b0250) 1991; 16 Krengel, Schlichting, Scherer, Schumann, Frech, John (b0230) 1990; 62 Karpov, Amiri, Bellamacina, Bellance, Breitenstein, Daniel (b0555) 2015; 6 Converso, Hartingh, Garbaccio, Tasber, Rickert, Fraley (b0620) 2009; 19 Zeng, Lu, Li, Feru, Quan, Gero (b0340) 2017; 24 Goodwin, Cianchetta, Burgoon, Healy, Mabon, Strobel (b0535) 2015; 6 Bera, Lu, Wales, Gondi, Gurbani, Nelson (b0215) 2019; 294 Manning, Whyte, Martinez, Hunter, Sudarsanam (b0470) 2002; 298 Dawson, Serrels, Stupack, Schlaepfer, Frame (b0770) 2021; 21 Pelish, Peterson, Salvarezza, Rodriguez-Boulan, Chen, Stamnes (b0690) 2006; 2 Ni, Chai, Wang, Li, Yu, Liu (b0080) 2021 Pettinger, Jones, Cheeseman (b0645) 2017; 56 Lu, Shen, Zhang (b0005) 2019; 52 Mortuza, Hermida, Pedersen, Segura-Bayona, Lopez-Mendez, Redondo (b0760) 2018; 9 Mysore, Zhou, Ambrogio, Li, Kapp, Lu (b0245) 2021; 28 Wylie, Schoepfer, Jahnke, Cowan-Jacob, Loo, Furet (b0585) 2017; 543 Montalvo-Ortiz, Castillo-Pichardo, Hernandez, Humphries-Bickley, De la Mota-Peynado, Cubano (b0720) 2012; 287 Deininger, Goldman, Lydon, Melo (b0495) 1997; 90 De Vita (b0635) 2021; 13 Ghosh, Samanta, Mondal, Liu (b0640) 2019; 14 Scheffzek, Ahmadian, Kabsch, Wiesmuller, Lautwein, Schmitz (b0225) 1997; 277 Roskoski (b0445) 2022; 175 Ramalingam, Yang, Lee, Kurata, Kim, John (b0750) 2018; 36 Motlagh, Wrabl, Li, Hilser (b0015) 2014; 508 Segura-Bayona, Stracker (b0765) 2019; 76 Milburn, Tong, deVos, Brunger, Yamaizumi, Nishimura (b0205) 1990; 247 Karlsson, Pedersen, Wang, Brakebusch (b0730) 2009; 1796 Chen, LaMarche, Chan, Fekkes, Garcia-Fortanet, Acker (b0040) 2016; 535 Li, Zhang, Hu, Wang, Song, Feng (b0110) 2011; 22 Huse, Kuriyan (b0460) 2002; 109 Hunter, Manandhar, Carrasco, Gurbani, Gondi, Westover (b0325) 2015; 13 Tran, Alexander, Dharmaiah, Agamasu, Nissley, McCormick (b0415) 2020; 117 Cheng, Jiang (b0070) 2019 Liu, Sabnis, Zhao, Zhang, Buhrlage, Jones (b0745) 2013; 20 Zhang, Adrian, Jahnke, Cowan-Jacob, Li, Iacob (b0575) 2010; 463 Wishart, Knox, Guo, Shrivastava, Hassanali, Stothard (b0020) 2006; 34 Kirsten, Mayer (b0185) 1967; 39 Lito, Solomon, Li, Hansen, Rosen (b0330) 2016; 351 Comess, Sun, Abad-Zapatero, Goedken, Gum, Borhani (b0625) 2011; 6 P. Novartis, Novartis. Study of JDQ443 in Comparison With Docetaxel in Participants With Locally Advanced or Metastatic KRAS G12C Mutant Non-small Cell Lung Cancer, 2024. Shanghai YingLi Pharmaceutical Co L. A Phase 1, Study of YL-15293 in Subjects With Advanced Solid Tumors With a KRAS G12C Mutation, 2022. Vasta, Peacock, Zheng, Walker, Zhang, Zimprich (b0365) 2021 Shang, Marchioni, Sipes, Evelyn, Jerabek-Willemsen, Duhr (b0735) 2012; 19 McNae, Kinkead, Malik, Yen, Walker, Swain (b0155) 2021; 12 Canon, Rex, Saiki, Mohr, Cooke, Bagal (b0350) 2019; 575 Adrian, Ding, Sim, Velentza, Sloan, Liu (b0570) 2006; 2 Bid, Roberts, Manchanda, Houghton (b0710) 2013; 12 Chen, Duan, Wei, Ning, Bi, Zhao (b0175) 2019; 28 Infante, Fecher, Falchook, Nallapareddy, Gordon, Becerra (b0270) 2012; 13 Sun, Burke, Phan, Burns, Olejniczak, Waterson (b0405) 2012; 51 Arias-Romero, Chernoff (b0685) 2013; 17 Hubbard, Till (b0465) 2000; 69 Blumenschein, Smit, Planchard, Kim, Cadranel, De Pas (b0265) 2015; 26 Jarvis (b0050) 2019; 97 Willumsen, Norris, Papageorge, Hubbert, Lowy (b0255) 1984; 3 Saladino, Gervasio (b0455) 2012; 12 Ganguly, Pramanik, Huang, Liberles, Heimark, Liu (b0375) 1997; 5 Senior, Evans, Jumper, Kirkpatrick, Sifre, Green (b0665) 2020; 577 Fodor, Price, Wang, Lu, Argintaru, Chen (b0030) 2018; 13 Whyte, Kirschmeier, Hockenberry, Nunez-Oliva, James, Catino (b0260) 1997; 272 Loomba, Kayali, Noureddin, Ruane, Lawitz, Bennett (b0180) 2018; 155 Hantschel, Nagar, Guettler, Kretzschmar, Dorey, Kuriyan (b0565) 2003; 112 Cheng, Chu, Chen, Feder, Mintier, Wu (b0160) 2007; 51 Cance, Kurenova, Marlowe, Golubovskaya (b0775) 2013; 6 Zhejiang Genfleet Therapeutics Co L, Genfleet Therapeutics I. A Study of GFH925 in Patients With Advanced Solid Tumors With KRAS G12C Mutations, 2024. Webb, Forouhar, Szu, Seetharaman, Tong, Barber (b0150) 2015; 523 Janes, Zhang, Li, Hansen, Peters, Guo (b0345) 2018; 172 Péczka, Orgován, Ábrányi-Balogh, Keserű (b0630) 2022; 17 Tomita, Hayashi, Suzuki, Oomori, Aramaki, Matsushita (b0550) 2013; 23 U. Augusta, H.J.K.C.C. Consortium, Asciminib as Initial Therapy for Patients With Chronic Myeloid Leukemia in Chronic Phase, 2025. Klüter, Grütter, Naqvi, Rabiller, Simard, Pawar (b0540) 2010; 53 Kamata, Mitsuya, Nishimura, Eiki, Nagata (b0095) 2004; 12 Rettenmaier, Sadowsky, Thomsen, Chen, Doak, Arkin (b0615) 2014; 111 Heinrich, Gradler, Bottcher, Blaukat, Shutes (b0530) 2010; 1 Prior, Lewis, Mattos (b0200) 2012; 72 Nussinov, Tsai (b0075) 2013; 153 Merriam-Webster. Merriam-Webster. Lamba, Ghosh (b0485) 2012; 18 Ohren, Chen, Pavlovsky, Whitehead, Zhang, Kuffa (b0510) 2004; 11 Blume-Jensen, Hunter (b0430) 2001; 411 Lu, Smaill, Ding (b0045) 2020; 59 Stephen, Esposito, Bagni, McCormick (b0440) 2014; 25 Taveras, Remiszewski, Doll, Cesarz, Huang, Kirschmeier (b0385) 1997; 5 Bridges (b0505) 1998 Becher, Savitski, Savitski, Hopf, Bantscheff, Drewes (b0475) 2013; 8 Yuan, Tam, Simplaceanu, Ho (b0090) 2015; 115 Jakob, Bassett, Ng, Curry, Joseph, Alvarado (b0740) 2012; 118 Moore, Rosenberg, McCormick, Malek (b0025) 2020; 19 Garcia Fortanet, Chen, Chen, Chen, Deng, Firestone (b0035) 2016; 59 Moret, Liu, Gyori, Bachman, Steppi, Hug (b0450) 2021 Simard, Klüter, Grütter, Getlik, Rabiller, Rode (b0545) 2009; 5 Mackay, Hall (b0725) 1998; 273 Zhao, Xie, Bourne (b0560) 2017; 12 Biondi, Cheung, Casamayor, Deak, Currie, Alessi (b0605) 2000; 19 Jia, Yun, Park, Ercan, Manuia, Juarez (b0525) 2016; 534 Johnson, Pringle (b0680) 1990; 111 L. PegBio Co, Clinical Trial for the Investigational Drug (PB-201) in Subjects With Type 2 Diabetes Mellitus, 2019. Wang, Rajput, Watabe, Liao, Cao (b0170) 2010; 2 Wakeling, Guy, Woodburn, Ashton, Curry, Barker (b0490) 2002; 62 P. Novartis, Novartis. A Study of Oral Asciminib Versus Other TKIs in Adult Patients With Newly Diagnosed Ph+ CML-CP, 2024. Ostrem, Peters, Sos, Wells, Shokat (b0320) 2013; 503 Sadowsky, Burlingame, Wolan, McClendon, Jacobson, Wells (b0610) 2011; 108 Sola-Penna, Da Silva, Coelho, Marinho-Carvalho, Zancan (b0140) 2010; 62 Meyers, Bryan, McFarland, Weir, Sizemore, Xu (b0670) 2017; 49 Gao, Dickerson, Guo, Zheng, Zheng (b0715) 2004; 101 Harvey (b0190) 1964; 204 Hunter, Gurbani, Ficarro, Carrasco, Lim, Choi (b0395) 2014; 111 A.C. Dar, K.M. Shokat, The Evolution of Protein Kinase Inhibitors from Antagonists to Agonists of Cellular Signaling, in: R.D. Kornberg, C.R.H. Raetz, J.E. Rothman, J.W. Thorner (Eds.), Annual Review of Biochemistry, Vol 802011. p. 769-95. Poulin, Bera, Lu, Lin, Strasser, Paulo (b0210) 2019; 9 Pao, Miller, Politi, Riely, Somwar, Zakowski (b0755) 2005; 2 Nassar, Horn, Herrmann, Scherer, McCormick, Wittinghofer (b0360) 1995; 375 Eli L, Company. A Study of LY2599506 (Oral Agent Medication: Glucokinase Activator 1) in Type 2 Diabetes Mellitus. 2010. Iacob, Zhang, Gray, Engen (b0580) 2011; 6 L. Eli, Company. A Study of LY3499446 in Participants With Advanced Solid Tumors With KRAS G12C Mutation, 2020. Xiong, Lu, Hunter, Li, Scott, Choi (b0400) 2017; 8 Bagal, Omoto, Blakemore, Bungay, Bilsland, Clarke (b0520) 2018; 62 Lu, Bera, Gondi, Westover (b0240) 2018; 57 Matschinsky, Wilson (b0100) 2019; 10 Hong, Fakih, Strickler, Desai, Durm, Shapiro (b0275) 2020; 383 Ashwell, Lapierre, Brassard, Bresciano, Bull, Cornell-Kennon (b0515) 2012; 55 Abdeldayem, Raouf, Constantinescu, Moriggl, Gunning (b0500) 2020; 49 Perutz (b0085) 1970; 228 Ambrogio, Kohler, Zhou, Wang, Paranal, Li (b0355) 2018; 172 Friesland, Zhao, Chen, Wang, Zhou, Lu (b0695) 2013; 110 Patricelli, Janes, Li, Hansen, Peters, Kessler (b0335) 2016; 6 Nakajima, Drezner, Li, Mishra-Kalyani, Liu, Zhao (b0655) 2021 Zhu, Zhu, Li, Li, Jin, Hu (b0105) 2018; 20 Grimsby, Sarabu, Corbett, Haynes, Bizzarro, Coffey (b0120) 2003; 301 Hansen, Peters, Babbar, Chen, Feng, Janes (b0370) 2018; 25 Fabbro, Cowan-Jacob, Moebitz (b0435) 2015; 172 Heasman, Ridley (b0705) 2008; 9 Monod, Jacob (b0060) 1961 Jacobio Pharmaceuticals Co L. FIH Study of JAB-21822 in Adult Patients With Advanced Solid Tumors Harboring KRAS G12C Mutation in China, 2025. Ganguly, Wang, Pramanik, Doll, Snow, Taveras (b0380) 1998; 37 P. Novartis, Novartis. Study of Efficacy and Safety of CML-CP Patients Treated With Asciminib Versus Best Available Therapy, Previously Treated With 2 or More Tyrosine Kinase Inhibitors, 2023. Kloos, Bruser, Kirchberger, Schoneberg, Strater (b0145) 2015; 469 Attwood, Fabbro, Sokolov, Knapp, Schioth (b0010) 2021; 20 Dawson (10.1016/j.jmb.2022.167626_b0770) 2021; 21 Kirsten (10.1016/j.jmb.2022.167626_b0185) 1967; 39 10.1016/j.jmb.2022.167626_b0290 Riely (10.1016/j.jmb.2022.167626_b0280) 2021; 16 10.1016/j.jmb.2022.167626_b0055 10.1016/j.jmb.2022.167626_b0295 Grimsby (10.1016/j.jmb.2022.167626_b0120) 2003; 301 Hong (10.1016/j.jmb.2022.167626_b0700) 2013; 288 Yuan (10.1016/j.jmb.2022.167626_b0090) 2015; 115 Bagal (10.1016/j.jmb.2022.167626_b0520) 2018; 62 Simons (10.1016/j.jmb.2022.167626_b0425) 2000; 1 Webb (10.1016/j.jmb.2022.167626_b0150) 2015; 523 Chen (10.1016/j.jmb.2022.167626_b0040) 2016; 535 Nussinov (10.1016/j.jmb.2022.167626_b0075) 2013; 153 Comess (10.1016/j.jmb.2022.167626_b0625) 2011; 6 Adrian (10.1016/j.jmb.2022.167626_b0570) 2006; 2 Hubbard (10.1016/j.jmb.2022.167626_b0465) 2000; 69 Loomba (10.1016/j.jmb.2022.167626_b0180) 2018; 155 Zhang (10.1016/j.jmb.2022.167626_b0575) 2010; 463 Hong (10.1016/j.jmb.2022.167626_b0275) 2020; 383 Lamba (10.1016/j.jmb.2022.167626_b0485) 2012; 18 Fodor (10.1016/j.jmb.2022.167626_b0030) 2018; 13 10.1016/j.jmb.2022.167626_b0285 Blume-Jensen (10.1016/j.jmb.2022.167626_b0430) 2001; 411 Meyers (10.1016/j.jmb.2022.167626_b0670) 2017; 49 Patricelli (10.1016/j.jmb.2022.167626_b0335) 2016; 6 Tsherniak (10.1016/j.jmb.2022.167626_b0675) 2017; 170 Monod (10.1016/j.jmb.2022.167626_b0060) 1961 Janes (10.1016/j.jmb.2022.167626_b0345) 2018; 172 Perutz (10.1016/j.jmb.2022.167626_b0085) 1970; 228 10.1016/j.jmb.2022.167626_b0600 Lu (10.1016/j.jmb.2022.167626_b0045) 2020; 59 McNae (10.1016/j.jmb.2022.167626_b0155) 2021; 12 Ambrogio (10.1016/j.jmb.2022.167626_b0355) 2018; 172 Biondi (10.1016/j.jmb.2022.167626_b0605) 2000; 19 Canon (10.1016/j.jmb.2022.167626_b0350) 2019; 575 Moret (10.1016/j.jmb.2022.167626_b0450) 2021 Arias-Romero (10.1016/j.jmb.2022.167626_b0685) 2013; 17 Gunasekaran (10.1016/j.jmb.2022.167626_b0065) 2004; 57 Bera (10.1016/j.jmb.2022.167626_b0215) 2019; 294 Ashwell (10.1016/j.jmb.2022.167626_b0515) 2012; 55 Simard (10.1016/j.jmb.2022.167626_b0545) 2009; 5 Ostrem (10.1016/j.jmb.2022.167626_b0320) 2013; 503 10.1016/j.jmb.2022.167626_b0595 Xiong (10.1016/j.jmb.2022.167626_b0400) 2017; 8 Stephen (10.1016/j.jmb.2022.167626_b0440) 2014; 25 Shang (10.1016/j.jmb.2022.167626_b0735) 2012; 19 Hunkeler (10.1016/j.jmb.2022.167626_b0165) 2018; 558 10.1016/j.jmb.2022.167626_b0590 Jia (10.1016/j.jmb.2022.167626_b0525) 2016; 534 Huse (10.1016/j.jmb.2022.167626_b0460) 2002; 109 Zeng (10.1016/j.jmb.2022.167626_b0340) 2017; 24 Wylie (10.1016/j.jmb.2022.167626_b0585) 2017; 543 Ganguly (10.1016/j.jmb.2022.167626_b0380) 1998; 37 Cance (10.1016/j.jmb.2022.167626_b0775) 2013; 6 Sola-Penna (10.1016/j.jmb.2022.167626_b0140) 2010; 62 Fabbro (10.1016/j.jmb.2022.167626_b0435) 2015; 172 Jarvis (10.1016/j.jmb.2022.167626_b0050) 2019; 97 Zhu (10.1016/j.jmb.2022.167626_b0105) 2018; 20 Krengel (10.1016/j.jmb.2022.167626_b0230) 1990; 62 Lim (10.1016/j.jmb.2022.167626_b0390) 2014; 53 Bid (10.1016/j.jmb.2022.167626_b0710) 2013; 12 Hantschel (10.1016/j.jmb.2022.167626_b0565) 2003; 112 Goody (10.1016/j.jmb.2022.167626_b0250) 1991; 16 Ullrich (10.1016/j.jmb.2022.167626_b0420) 1990; 61 Iacob (10.1016/j.jmb.2022.167626_b0580) 2011; 6 Pettinger (10.1016/j.jmb.2022.167626_b0645) 2017; 56 Johnson (10.1016/j.jmb.2022.167626_b0680) 1990; 111 Ghosh (10.1016/j.jmb.2022.167626_b0640) 2019; 14 Mysore (10.1016/j.jmb.2022.167626_b0245) 2021; 28 Mortuza (10.1016/j.jmb.2022.167626_b0760) 2018; 9 Scheffzek (10.1016/j.jmb.2022.167626_b0225) 1997; 277 Wang (10.1016/j.jmb.2022.167626_b0170) 2010; 2 Heinrich (10.1016/j.jmb.2022.167626_b0530) 2010; 1 Sun (10.1016/j.jmb.2022.167626_b0405) 2012; 51 Tomita (10.1016/j.jmb.2022.167626_b0550) 2013; 23 Nassar (10.1016/j.jmb.2022.167626_b0360) 1995; 375 Pao (10.1016/j.jmb.2022.167626_b0755) 2005; 2 Lu (10.1016/j.jmb.2022.167626_b0240) 2018; 57 Liu (10.1016/j.jmb.2022.167626_b0115) 2021; 42 10.1016/j.jmb.2022.167626_b0135 Milburn (10.1016/j.jmb.2022.167626_b0205) 1990; 247 Zhao (10.1016/j.jmb.2022.167626_b0560) 2017; 12 Lu (10.1016/j.jmb.2022.167626_b0005) 2019; 52 10.1016/j.jmb.2022.167626_b0130 Sutanto (10.1016/j.jmb.2022.167626_b0650) 2020; 11 Jakob (10.1016/j.jmb.2022.167626_b0740) 2012; 118 Matschinsky (10.1016/j.jmb.2022.167626_b0100) 2019; 10 Bera (10.1016/j.jmb.2022.167626_b0235) 2020; 112 Klüter (10.1016/j.jmb.2022.167626_b0540) 2010; 53 Bridges (10.1016/j.jmb.2022.167626_b0505) 1998 Rettenmaier (10.1016/j.jmb.2022.167626_b0615) 2014; 111 Ohren (10.1016/j.jmb.2022.167626_b0510) 2004; 11 Hunter (10.1016/j.jmb.2022.167626_b0325) 2015; 13 Cheng (10.1016/j.jmb.2022.167626_b0070) 2019 Vasta (10.1016/j.jmb.2022.167626_b0365) 2021 Lito (10.1016/j.jmb.2022.167626_b0330) 2016; 351 Ganguly (10.1016/j.jmb.2022.167626_b0375) 1997; 5 Converso (10.1016/j.jmb.2022.167626_b0620) 2009; 19 Kamata (10.1016/j.jmb.2022.167626_b0095) 2004; 12 Li (10.1016/j.jmb.2022.167626_b0110) 2011; 22 Friesland (10.1016/j.jmb.2022.167626_b0695) 2013; 110 Wakeling (10.1016/j.jmb.2022.167626_b0490) 2002; 62 Nakajima (10.1016/j.jmb.2022.167626_b0655) 2021 Harvey (10.1016/j.jmb.2022.167626_b0190) 1964; 204 10.1016/j.jmb.2022.167626_b0480 Ramalingam (10.1016/j.jmb.2022.167626_b0750) 2018; 36 Senior (10.1016/j.jmb.2022.167626_b0665) 2020; 577 10.1016/j.jmb.2022.167626_b0125 Tran (10.1016/j.jmb.2022.167626_b0415) 2020; 117 Péczka (10.1016/j.jmb.2022.167626_b0630) 2022; 17 Montalvo-Ortiz (10.1016/j.jmb.2022.167626_b0720) 2012; 287 Saladino (10.1016/j.jmb.2022.167626_b0455) 2012; 12 Liu (10.1016/j.jmb.2022.167626_b0745) 2013; 20 Willumsen (10.1016/j.jmb.2022.167626_b0255) 1984; 3 Hunter (10.1016/j.jmb.2022.167626_b0395) 2014; 111 Prior (10.1016/j.jmb.2022.167626_b0200) 2012; 72 Motlagh (10.1016/j.jmb.2022.167626_b0015) 2014; 508 Karpov (10.1016/j.jmb.2022.167626_b0555) 2015; 6 Whyte (10.1016/j.jmb.2022.167626_b0260) 1997; 272 10.1016/j.jmb.2022.167626_b0310 Ni (10.1016/j.jmb.2022.167626_b0080) 2021 Chen (10.1016/j.jmb.2022.167626_b0175) 2019; 28 Abdeldayem (10.1016/j.jmb.2022.167626_b0500) 2020; 49 De Vita (10.1016/j.jmb.2022.167626_b0635) 2021; 13 Segura-Bayona (10.1016/j.jmb.2022.167626_b0765) 2019; 76 Becher (10.1016/j.jmb.2022.167626_b0475) 2013; 8 Poulin (10.1016/j.jmb.2022.167626_b0210) 2019; 9 10.1016/j.jmb.2022.167626_b0315 Cheng (10.1016/j.jmb.2022.167626_b0160) 2007; 51 Deininger (10.1016/j.jmb.2022.167626_b0495) 1997; 90 Karlsson (10.1016/j.jmb.2022.167626_b0730) 2009; 1796 Lu (10.1016/j.jmb.2022.167626_b0220) 2015; 5 Goodwin (10.1016/j.jmb.2022.167626_b0535) 2015; 6 Gao (10.1016/j.jmb.2022.167626_b0715) 2004; 101 Wishart (10.1016/j.jmb.2022.167626_b0020) 2006; 34 Garcia Fortanet (10.1016/j.jmb.2022.167626_b0035) 2016; 59 Sadowsky (10.1016/j.jmb.2022.167626_b0610) 2011; 108 Ellis (10.1016/j.jmb.2022.167626_b0195) 1981; 292 Kloos (10.1016/j.jmb.2022.167626_b0145) 2015; 469 Moore (10.1016/j.jmb.2022.167626_b0025) 2020; 19 Roskoski (10.1016/j.jmb.2022.167626_b0445) 2022; 175 Blumenschein (10.1016/j.jmb.2022.167626_b0265) 2015; 26 Hansen (10.1016/j.jmb.2022.167626_b0370) 2018; 25 Mackay (10.1016/j.jmb.2022.167626_b0725) 1998; 273 10.1016/j.jmb.2022.167626_b0300 Infante (10.1016/j.jmb.2022.167626_b0270) 2012; 13 Pelish (10.1016/j.jmb.2022.167626_b0690) 2006; 2 Taveras (10.1016/j.jmb.2022.167626_b0385) 1997; 5 Manning (10.1016/j.jmb.2022.167626_b0470) 2002; 298 10.1016/j.jmb.2022.167626_b0305 Heasman (10.1016/j.jmb.2022.167626_b0705) 2008; 9 Attwood (10.1016/j.jmb.2022.167626_b0010) 2021; 20 Kessler (10.1016/j.jmb.2022.167626_b0410) 2019; 116 |
| References_xml | – volume: 20 start-page: 146 year: 2013 end-page: 159 ident: b0745 article-title: Developing irreversible inhibitors of the protein kinase cysteinome publication-title: Chem. Biol. – volume: 112 start-page: 845 year: 2003 end-page: 857 ident: b0565 article-title: A myristoyl/phosphotyrosine switch regulates c-Abl publication-title: Cell – volume: 11 start-page: 1192 year: 2004 end-page: 1197 ident: b0510 article-title: Structures of human MAP kinase kinase 1 (MEK1) and MEK2 describe novel noncompetitive kinase inhibition publication-title: Nat. Struct. Mol. Biol. – reference: Jacobio Pharmaceuticals Co L. FIH Study of JAB-21822 in Adult Patients With Advanced Solid Tumors Harboring KRAS G12C Mutation in China, 2025. – volume: 28 start-page: 847 year: 2021 end-page: 857 ident: b0245 article-title: A structural model of a Ras-Raf signalosome publication-title: Nat. Struct. Mol. Biol. – volume: 12 start-page: 1052 year: 2021 ident: b0155 article-title: Fast acting allosteric phosphofructokinase inhibitors block trypanosome glycolysis and cure acute African trypanosomiasis in mice publication-title: Nat. Commun. – volume: 277 start-page: 333 year: 1997 end-page: 338 ident: b0225 article-title: The Ras-RasGAP complex: structural basis for GTPase activation and its loss in oncogenic Ras mutants publication-title: Science – volume: 12 start-page: 1925 year: 2013 end-page: 1934 ident: b0710 article-title: RAC1: an emerging therapeutic option for targeting cancer angiogenesis and metastasis publication-title: Mol. Cancer Ther. – start-page: 1 year: 2019 end-page: 23 ident: b0070 article-title: Allostery in Drug Development publication-title: Protein Allostery in Drug Discovery – volume: 53 start-page: 357 year: 2010 end-page: 367 ident: b0540 article-title: Displacement assay for the detection of stabilizers of inactive kinase conformations publication-title: J. Med. Chem. – volume: 1 start-page: 31 year: 2000 end-page: 39 ident: b0425 article-title: Lipid rafts and signal transduction publication-title: Nat. Rev. Mol. Cell Biol. – volume: 14 start-page: 889 year: 2019 end-page: 906 ident: b0640 article-title: Covalent Inhibition in Drug Discovery publication-title: ChemMedChem – volume: 16 start-page: S751 year: 2021 end-page: S752 ident: b0280 article-title: KRYSTAL-1: Activity and preliminary pharmacodynamic (PD) analysis of adagrasib (MRTX849) in patients (Pts) with advanced non-small cell lung cancer (NSCLC) harboring KRASG12C mutation publication-title: J. Thoracic Oncol. – volume: 301 start-page: 370 year: 2003 end-page: 373 ident: b0120 article-title: Allosteric activators of glucokinase: potential role in diabetes therapy publication-title: Science – volume: 463 start-page: 501 year: 2010 end-page: 506 ident: b0575 article-title: Targeting Bcr-Abl by combining allosteric with ATP-binding-site inhibitors publication-title: Nature – volume: 534 start-page: 129 year: 2016 end-page: 132 ident: b0525 article-title: Overcoming EGFR (T790M) and EGFR (C797S) resistance with mutant-selective allosteric inhibitors publication-title: Nature – volume: 383 start-page: 1207 year: 2020 end-page: 1217 ident: b0275 article-title: KRAS(G12C) Inhibition with Sotorasib in Advanced Solid Tumors publication-title: N. Engl. J. Med. – volume: 22 start-page: 73 year: 2011 end-page: 76 ident: b0110 article-title: Design, synthesis and biological evaluation of novel glucokinase activators publication-title: Chin. Chem. Lett. – reference: Shanghai YingLi Pharmaceutical Co L. A Phase 1, Study of YL-15293 in Subjects With Advanced Solid Tumors With a KRAS G12C Mutation, 2022. – volume: 272 start-page: 14459 year: 1997 end-page: 14464 ident: b0260 article-title: K- and N-Ras are geranylgeranylated in cells treated with farnesyl protein transferase inhibitors publication-title: J. Biol. Chem. – volume: 287 start-page: 13228 year: 2012 end-page: 13238 ident: b0720 article-title: Characterization of EHop-016, novel small molecule inhibitor of Rac GTPase publication-title: J. Biol. Chem. – volume: 6 year: 2013 ident: b0775 article-title: Disrupting the scaffold to improve focal adhesion kinase-targeted cancer therapeutics publication-title: Sci. Signal – volume: 19 start-page: 699 year: 2012 end-page: 710 ident: b0735 article-title: Rational design of small molecule inhibitors targeting RhoA subfamily Rho GTPases publication-title: Chem. Biol. – volume: 12 year: 2017 ident: b0560 article-title: Insights into the binding mode of MEK type-III inhibitors. A step towards discovering and designing allosteric kinase inhibitors across the human kinome publication-title: PLoS ONE – volume: 543 start-page: 733 year: 2017 end-page: 737 ident: b0585 article-title: The allosteric inhibitor ABL001 enables dual targeting of BCR-ABL1 publication-title: Nature – volume: 17 start-page: 413 year: 2022 end-page: 422 ident: b0630 article-title: Electrophilic warheads in covalent drug discovery: an overview publication-title: Expert Opin. Drug Discov. – volume: 411 start-page: 355 year: 2001 end-page: 365 ident: b0430 article-title: Oncogenic kinase signalling publication-title: Nature – year: 2021 ident: b0080 article-title: Along the allostery stream: Recent advances in computational methods for allosteric drug discovery publication-title: WIREs Comput. Mol. Sci. – volume: 13 start-page: 773 year: 2012 end-page: 781 ident: b0270 article-title: Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial publication-title: Lancet Oncol. – year: 2021 ident: b0655 article-title: FDA Approval Summary: Sotorasib for KRAS G12C-Mutated Metastatic NSCLC publication-title: Clin. Cancer Res. – volume: 19 start-page: 979 year: 2000 end-page: 988 ident: b0605 article-title: Identification of a pocket in the PDK1 kinase domain that interacts with PIF and the C-terminal residues of PKA publication-title: EMBO J. – volume: 228 start-page: 726 year: 1970 end-page: 739 ident: b0085 article-title: Stereochemistry of cooperative effects in haemoglobin publication-title: Nature – volume: 62 start-page: 791 year: 2010 end-page: 796 ident: b0140 article-title: Regulation of mammalian muscle type 6-phosphofructo-1-kinase and its implication for the control of the metabolism publication-title: IUBMB Life – volume: 5 start-page: 817 year: 1997 end-page: 820 ident: b0375 article-title: Detection and structural characterization of ras oncoprotein-inhibitors complexes by electrospray mass spectrometry publication-title: Bioorg. Med. Chem. – volume: 153 start-page: 293 year: 2013 end-page: 305 ident: b0075 article-title: Allostery in disease and in drug discovery publication-title: Cell – volume: 9 start-page: 738 year: 2019 end-page: 755 ident: b0210 article-title: Tissue-Specific Oncogenic Activity of KRAS(A146T) publication-title: Cancer Discov. – volume: 523 start-page: 111 year: 2015 end-page: 114 ident: b0150 article-title: Structures of human phosphofructokinase-1 and atomic basis of cancer-associated mutations publication-title: Nature – volume: 2 start-page: 95 year: 2006 end-page: 102 ident: b0570 article-title: Allosteric inhibitors of Bcr-abl-dependent cell proliferation publication-title: Nat. Chem. Biol. – volume: 97 year: 2019 ident: b0050 article-title: Drug hunters explore allostery’s advantages publication-title: Chem. & Eng. News – volume: 292 start-page: 506 year: 1981 end-page: 511 ident: b0195 article-title: The p21 src genes of Harvey and Kirsten sarcoma viruses originate from divergent members of a family of normal vertebrate genes publication-title: Nature – volume: 5 start-page: 572 year: 2015 end-page: 578 ident: b0220 article-title: Structural dataset for the fast-exchanging KRAS G13D publication-title: Data Brief. – volume: 170 year: 2017 ident: b0675 article-title: Defining a Cancer Dependency Map publication-title: Cell – volume: 36 start-page: 841 year: 2018 end-page: 849 ident: b0750 article-title: Osimertinib as first-line treatment of EGFR mutation-positive advanced non-small-cell lung cancer publication-title: J. Clin. Oncol. – volume: 535 start-page: 148 year: 2016 end-page: 152 ident: b0040 article-title: Allosteric inhibition of SHP2 phosphatase inhibits cancers driven by receptor tyrosine kinases publication-title: Nature – volume: 57 start-page: 433 year: 2004 end-page: 443 ident: b0065 article-title: Is allostery an intrinsic property of all dynamic proteins? publication-title: Proteins: Structure, Function, and Bioinformatics. – volume: 5 start-page: 125 year: 1997 end-page: 133 ident: b0385 article-title: Ras oncoprotein inhibitors: the discovery of potent, ras nucleotide exchange inhibitors and the structural determination of a drug-protein complex publication-title: Bioorg. Med. Chem. – volume: 10 start-page: 148 year: 2019 ident: b0100 article-title: The Central Role of Glucokinase in Glucose Homeostasis: A Perspective 50 Years After Demonstrating the Presence of the Enzyme in Islets of Langerhans publication-title: Front. Physiol. – volume: 558 start-page: 470 year: 2018 end-page: 474 ident: b0165 article-title: Structural basis for regulation of human acetyl-CoA carboxylase publication-title: Nature – reference: P. Novartis, Novartis. Study of Efficacy and Safety of CML-CP Patients Treated With Asciminib Versus Best Available Therapy, Previously Treated With 2 or More Tyrosine Kinase Inhibitors, 2023. – volume: 25 start-page: 454 year: 2018 end-page: 462 ident: b0370 article-title: The reactivity-driven biochemical mechanism of covalent KRAS(G12C) inhibitors publication-title: Nat. Struct. Mol. Biol. – volume: 28 start-page: 917 year: 2019 end-page: 930 ident: b0175 article-title: Acetyl-CoA carboxylase (ACC) as a therapeutic target for metabolic syndrome and recent developments in ACC1/2 inhibitors publication-title: Expert Opin. Invest. Drugs – reference: P. Novartis, Novartis. Study of JDQ443 in Comparison With Docetaxel in Participants With Locally Advanced or Metastatic KRAS G12C Mutant Non-small Cell Lung Cancer, 2024. – volume: 351 start-page: 604 year: 2016 end-page: 608 ident: b0330 article-title: Allele-specific inhibitors inactivate mutant KRAS G12C by a trapping mechanism publication-title: Science – volume: 375 start-page: 554 year: 1995 end-page: 560 ident: b0360 article-title: The 2.2 Å crystal structure of the Ras-binding domain of the serine/threonine kinase c-Raf1 in complex with RaplA and a GTP analogue publication-title: Nature – reference: Eli L, Company. A Study of LY2599506 (Oral Agent Medication: Glucokinase Activator 1) in Type 2 Diabetes Mellitus. 2010. – volume: 175 year: 2022 ident: b0445 article-title: Properties of FDA-approved small molecule protein kinase inhibitors: A 2022 update publication-title: Pharmacol. Res. – volume: 2 year: 2005 ident: b0755 article-title: Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain publication-title: PLoS Med. – volume: 57 start-page: 324 year: 2018 end-page: 333 ident: b0240 article-title: KRAS Switch Mutants D33E and A59G Crystallize in the State 1 Conformation publication-title: Biochemistry – volume: 18 start-page: 2936 year: 2012 end-page: 2945 ident: b0485 article-title: New directions in targeting protein kinases: focusing upon true allosteric and bivalent inhibitors publication-title: Curr. Pharm. Des. – volume: 51 start-page: 6140 year: 2012 end-page: 6143 ident: b0405 article-title: Discovery of small molecules that bind to K-Ras and inhibit Sos-mediated activation publication-title: Angew. Chem. Int. Ed. Engl. – volume: 9 start-page: 2535 year: 2018 ident: b0760 article-title: Molecular basis of Tousled-Like Kinase 2 activation publication-title: Nat. Commun. – volume: 108 start-page: 6056 year: 2011 end-page: 6061 ident: b0610 article-title: Turning a protein kinase on or off from a single allosteric site via disulfide trapping publication-title: Proc. Natl. Acad. Sci. U. S. A. – volume: 9 start-page: 690 year: 2008 end-page: 701 ident: b0705 article-title: Mammalian Rho GTPases: new insights into their functions from in vivo studies publication-title: Nat. Rev. Mol. Cell Biol. – volume: 508 start-page: 331 year: 2014 end-page: 339 ident: b0015 article-title: The ensemble nature of allostery publication-title: Nature – volume: 49 start-page: 2617 year: 2020 end-page: 2687 ident: b0500 article-title: Advances in covalent kinase inhibitors publication-title: Chem. Soc. Rev. – volume: 72 start-page: 2457 year: 2012 end-page: 2467 ident: b0200 article-title: A comprehensive survey of Ras mutations in cancer publication-title: Cancer Res. – volume: 2 start-page: 15 year: 2010 end-page: 26 ident: b0170 article-title: Acetyl-CoA carboxylase-alpha as a novel target for cancer therapy publication-title: Front Biosci. – volume: 51 start-page: 11 year: 2007 end-page: 21 ident: b0160 article-title: Expression, purification, and characterization of human and rat acetyl coenzyme A carboxylase (ACC) isozymes publication-title: Protein Expr. Purif. – volume: 62 start-page: 539 year: 1990 end-page: 548 ident: b0230 article-title: Three-dimensional structures of H-ras p21 mutants: molecular basis for their inability to function as signal switch molecules publication-title: Cell – volume: 90 start-page: 3691 year: 1997 end-page: 3698 ident: b0495 article-title: The tyrosine kinase inhibitor CGP57148B selectively inhibits the growth of BCR-ABL-positive cells publication-title: Blood – volume: 111 start-page: 18590 year: 2014 end-page: 18595 ident: b0615 article-title: A small-molecule mimic of a peptide docking motif inhibits the protein kinase PDK1 publication-title: Proc. Natl. Acad. Sci. U. S. A. – volume: 76 start-page: 3827 year: 2019 end-page: 3841 ident: b0765 article-title: The Tousled-like kinases regulate genome and epigenome stability: implications in development and disease publication-title: Cell. Mol. Life Sci. – volume: 16 start-page: 327 year: 1991 end-page: 328 ident: b0250 article-title: Affinity of guanine nucleotide binding proteins for their ligands: facts and artefacts publication-title: Trends Biochem. Sci. – volume: 172 year: 2018 ident: b0345 article-title: Targeting KRAS Mutant Cancers with a Covalent G12C-Specific Inhibitor publication-title: Cell – volume: 19 start-page: 1240 year: 2009 end-page: 1244 ident: b0620 article-title: Development of thioquinazolinones, allosteric Chk1 kinase inhibitors publication-title: Bioorg. Med. Chem. Lett. – volume: 17 start-page: 1263 year: 2013 end-page: 1273 ident: b0685 article-title: Targeting Cdc42 in cancer publication-title: Expert Opin. Ther. Targets. – volume: 116 start-page: 15823 year: 2019 end-page: 15829 ident: b0410 article-title: Drugging an undruggable pocket on KRAS publication-title: Proc. Natl. Acad. Sci. U. S. A. – volume: 20 start-page: 2113 year: 2018 end-page: 2120 ident: b0105 article-title: Dorzagliatin (HMS5552), a novel dual-acting glucokinase activator, improves glycaemic control and pancreatic beta-cell function in patients with type 2 diabetes: A 28-day treatment study using biomarker-guided patient selection publication-title: Diabetes Obes. Metab. – volume: 273 start-page: 20685 year: 1998 end-page: 20688 ident: b0725 publication-title: Rho GTPases. J Biol Chem. – volume: 6 start-page: 316 year: 2016 end-page: 329 ident: b0335 article-title: Selective Inhibition of Oncogenic KRAS Output with Small Molecules Targeting the Inactive State publication-title: Cancer Discov. – volume: 56 start-page: 15200 year: 2017 end-page: 15209 ident: b0645 article-title: Lysine-Targeting Covalent Inhibitors publication-title: Angew. Chem. Int. Ed. Engl. – volume: 3 start-page: 2581 year: 1984 end-page: 2585 ident: b0255 article-title: Harvey murine sarcoma virus p21 ras protein: biological and biochemical significance of the cysteine nearest the carboxy terminus publication-title: EMBO J. – volume: 118 start-page: 4014 year: 2012 end-page: 4023 ident: b0740 article-title: NRAS mutation status is an independent prognostic factor in metastatic melanoma publication-title: Cancer-Am Cancer Soc. – volume: 21 start-page: 313 year: 2021 end-page: 324 ident: b0770 article-title: Targeting FAK in anticancer combination therapies publication-title: Nat. Rev. Cancer – volume: 110 start-page: 1261 year: 2013 end-page: 1266 ident: b0695 article-title: Small molecule targeting Cdc42-intersectin interaction disrupts Golgi organization and suppresses cell motility publication-title: Proc. Natl. Acad. Sci. U. S. A. – volume: 37 start-page: 15631 year: 1998 end-page: 15637 ident: b0380 article-title: Interaction of a novel GDP exchange inhibitor with the Ras protein publication-title: Biochemistry – volume: 247 start-page: 939 year: 1990 end-page: 945 ident: b0205 article-title: Molecular switch for signal transduction: structural differences between active and inactive forms of protooncogenic ras proteins publication-title: Science – volume: 469 start-page: 421 year: 2015 end-page: 432 ident: b0145 article-title: Crystal structure of human platelet phosphofructokinase-1 locked in an activated conformation publication-title: Biochem. J. – volume: 26 start-page: 894 year: 2015 end-page: 901 ident: b0265 article-title: A randomized phase II study of the MEK1/MEK2 inhibitor trametinib (GSK1120212) compared with docetaxel in KRAS-mutant advanced non-small-cell lung cancer (NSCLC)dagger publication-title: Ann. Oncol. – volume: 53 start-page: 199 year: 2014 end-page: 204 ident: b0390 article-title: Therapeutic targeting of oncogenic K-Ras by a covalent catalytic site inhibitor publication-title: Angew. Chem. Int. Ed. Engl. – volume: 1796 start-page: 91 year: 2009 end-page: 98 ident: b0730 article-title: Rho GTPase function in tumorigenesis publication-title: Biochim. Biophys. Acta, Mol. Cell. Biol. Lipids – volume: 117 start-page: 3363 year: 2020 end-page: 3364 ident: b0415 article-title: The small molecule BI-2852 induces a nonfunctional dimer of KRAS publication-title: Proc. Natl. Acad. Sci. U. S. A. – volume: 61 start-page: 203 year: 1990 end-page: 212 ident: b0420 article-title: Signal transduction by receptors with tyrosine kinase activity publication-title: Cell – volume: 24 year: 2017 ident: b0340 article-title: Potent and Selective Covalent Quinazoline Inhibitors of KRAS G12C publication-title: Cell Chem. Biol. – volume: 111 start-page: 8895 year: 2014 end-page: 8900 ident: b0395 article-title: In situ selectivity profiling and crystal structure of SML-8-73-1, an active site inhibitor of oncogenic K-Ras G12C publication-title: Proc. Natl. Acad. Sci. U. S. A. – volume: 109 start-page: 275 year: 2002 end-page: 282 ident: b0460 article-title: The conformational plasticity of protein kinases publication-title: Cell – volume: 13 start-page: 1325 year: 2015 end-page: 1335 ident: b0325 article-title: Biochemical and Structural Analysis of Common Cancer-Associated KRAS Mutations publication-title: Mol. Cancer Res. – volume: 577 start-page: 706 year: 2020 end-page: 710 ident: b0665 article-title: Improved protein structure prediction using potentials from deep learning publication-title: Nature – volume: 59 start-page: 13764 year: 2020 end-page: 13776 ident: b0045 article-title: New Promise and Opportunities for Allosteric Kinase Inhibitors publication-title: Angew. Chem. Int. Ed. Engl. – volume: 6 start-page: 234 year: 2011 end-page: 244 ident: b0625 article-title: Discovery and characterization of non-ATP site inhibitors of the mitogen activated protein (MAP) kinases publication-title: ACS Chem. Biol. – volume: 172 year: 2018 ident: b0355 article-title: KRAS Dimerization Impacts MEK Inhibitor Sensitivity and Oncogenic Activity of Mutant KRAS publication-title: Cell – volume: 115 start-page: 1702 year: 2015 end-page: 1724 ident: b0090 article-title: New look at hemoglobin allostery publication-title: Chem. Rev. – volume: 112 start-page: 708 year: 2020 end-page: 717 ident: b0235 article-title: GTP hydrolysis is modulated by Arg34 in the RASopathy-associated KRAS(P34R) publication-title: Birth Defects Res. – reference: Merriam-Webster. Merriam-Webster. – reference: Zhejiang Genfleet Therapeutics Co L, Genfleet Therapeutics I. A Study of GFH925 in Patients With Advanced Solid Tumors With KRAS G12C Mutations, 2024. – volume: 155 year: 2018 ident: b0180 article-title: GS-0976 Reduces Hepatic Steatosis and Fibrosis Markers in Patients With Nonalcoholic Fatty Liver Disease publication-title: Gastroenterology – start-page: 389 year: 1961 end-page: 401 ident: b0060 article-title: General conclusions: teleonomic mechanisms in cellular metabolism, growth, and differentiation – reference: I. Revolution Medicines, Sanofi, Amgen, Combination Study of RMC-4630 and Sotorasib for NSCLC Subjects With KRASG12C Mutation After Failure of Prior Standard Therapies, 2023. – volume: 288 start-page: 8531 year: 2013 end-page: 8543 ident: b0700 article-title: Characterization of a Cdc42 protein inhibitor and its use as a molecular probe publication-title: J. Biol. Chem. – reference: L. Eli, Company. A Study of LY3499446 in Participants With Advanced Solid Tumors With KRAS G12C Mutation, 2020. – volume: 39 start-page: 311 year: 1967 end-page: 335 ident: b0185 article-title: Morphologic Responses to a Murine Erythroblastosis Virus<xref ref-type=“fn” rid=“FN1”>2</xref> publication-title: JNCI: J. Natl. Cancer Inst. – reference: P. Novartis, Novartis. A Study of Oral Asciminib Versus Other TKIs in Adult Patients With Newly Diagnosed Ph+ CML-CP, 2024. – volume: 13 start-page: 193 year: 2021 end-page: 210 ident: b0635 article-title: 10 years into the resurgence of covalent drugs publication-title: Future Med. Chem. – volume: 204 start-page: 1104 year: 1964 end-page: 1105 ident: b0190 article-title: An Unidentified Virus Which Causes the Rapid Production of Tumours in Mice publication-title: Nature – volume: 62 start-page: 247 year: 2018 end-page: 265 ident: b0520 article-title: Discovery of allosteric, potent, subtype selective, and peripherally restricted TrkA kinase inhibitors publication-title: J. Med. Chem. – volume: 11 start-page: 876 year: 2020 end-page: 884 ident: b0650 article-title: Covalent inhibitors: a rational approach to drug discovery publication-title: RSC Med. Chem. – volume: 49 start-page: 1779 year: 2017 end-page: 1784 ident: b0670 article-title: Computational correction of copy number effect improves specificity of CRISPR-Cas9 essentiality screens in cancer cells publication-title: Nat. Genet. – reference: U. Augusta, H.J.K.C.C. Consortium, Asciminib as Initial Therapy for Patients With Chronic Myeloid Leukemia in Chronic Phase, 2025. – volume: 13 start-page: 647 year: 2018 end-page: 656 ident: b0030 article-title: Dual Allosteric Inhibition of SHP2 Phosphatase publication-title: ACS Chem. Biol. – volume: 6 start-page: 53 year: 2015 end-page: 57 ident: b0535 article-title: Discovery of a type III inhibitor of LIM kinase 2 that binds in a DFG-out conformation publication-title: ACS Med. Chem. Lett. – volume: 12 start-page: 1889 year: 2012 end-page: 1895 ident: b0455 article-title: New insights in protein kinase conformational dynamics publication-title: Curr. Top. Med. Chem. – volume: 55 start-page: 5291 year: 2012 end-page: 5310 ident: b0515 article-title: Discovery and optimization of a series of 3-(3-Phenyl-3 H-imidazo [4, 5-b] pyridin-2-yl) pyridin-2-amines: orally bioavailable, selective, and potent ATP-independent Akt inhibitors publication-title: J. Med. Chem. – year: 2021 ident: b0450 article-title: A resource for exploring the understudied human kinome for research and therapeutic opportunities publication-title: bioRxiv – volume: 2 start-page: 39 year: 2006 end-page: 46 ident: b0690 article-title: Secramine inhibits Cdc42-dependent functions in cells and Cdc42 activation in vitro publication-title: Nat. Chem. Biol. – volume: 294 start-page: 13964 year: 2019 end-page: 13972 ident: b0215 article-title: Structural basis of the atypical activation mechanism of KRAS(V14I) publication-title: J. Biol. Chem. – volume: 42 year: 2021 ident: b0115 article-title: Safety, tolerability, pharmacokinetics, and pharmacodynamics of the glucokinase activator PB-201 and its effects on the glucose excursion profile in drug-naive Chinese patients with type 2 diabetes: a randomised controlled, crossover, single-centre phase 1 trial publication-title: EClinicalMedicine. – volume: 59 start-page: 7773 year: 2016 end-page: 7782 ident: b0035 article-title: Allosteric Inhibition of SHP2: Identification of a Potent, Selective, and Orally Efficacious Phosphatase Inhibitor publication-title: J. Med. Chem. – volume: 12 start-page: 429 year: 2004 end-page: 438 ident: b0095 article-title: Structural basis for allosteric regulation of the monomeric allosteric enzyme human glucokinase publication-title: Structure. – volume: 298 start-page: 1912 year: 2002 end-page: 1934 ident: b0470 article-title: The protein kinase complement of the human genome publication-title: Science – year: 1998 ident: b0505 article-title: Preparation of 2-phenylaminobenzoic acids and its amides as MEK inhibitors for treating or preventing septic shock publication-title: Warner Lambert Co. – volume: 6 start-page: 776 year: 2015 end-page: 781 ident: b0555 article-title: Optimization of a dibenzodiazepine hit to a potent and selective allosteric PAK1 inhibitor publication-title: ACS Med. Chem. Lett. – volume: 6 year: 2011 ident: b0580 article-title: Allosteric interactions between the myristate- and ATP-site of the Abl kinase publication-title: PLoS ONE – volume: 25 start-page: 272 year: 2014 end-page: 281 ident: b0440 article-title: Dragging ras back in the ring publication-title: Cancer Cell – volume: 172 start-page: 2675 year: 2015 end-page: 2700 ident: b0435 article-title: Ten things you should know about protein kinases: IUPHAR R eview 14 publication-title: Br. J. Pharmacol. – reference: L. PegBio Co, Clinical Trial for the Investigational Drug (PB-201) in Subjects With Type 2 Diabetes Mellitus, 2019. – reference: University of V. Effects of Modulators of Gluconeogenesis, Glycogenolysis and Glucokinase Activity, 2022. – volume: 19 start-page: 533 year: 2020 end-page: 552 ident: b0025 article-title: RAS-targeted therapies: is the undruggable drugged? publication-title: Nat. Rev. Drug Discov. – volume: 101 start-page: 7618 year: 2004 end-page: 7623 ident: b0715 article-title: Rational design and characterization of a Rac GTPase-specific small molecule inhibitor publication-title: Proc. Natl. Acad. Sci. U. S. A. – volume: 20 start-page: 839 year: 2021 end-page: 861 ident: b0010 article-title: Trends in kinase drug discovery: targets, indications and inhibitor design publication-title: Nat. Rev. Drug Discov. – volume: 575 start-page: 217 year: 2019 end-page: 223 ident: b0350 article-title: The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity publication-title: Nature – volume: 69 start-page: 373 year: 2000 end-page: 398 ident: b0465 article-title: Protein tyrosine kinase structure and function publication-title: Annu. Rev. Biochem. – reference: A.C. Dar, K.M. Shokat, The Evolution of Protein Kinase Inhibitors from Antagonists to Agonists of Cellular Signaling, in: R.D. Kornberg, C.R.H. Raetz, J.E. Rothman, J.W. Thorner (Eds.), Annual Review of Biochemistry, Vol 802011. p. 769-95. – volume: 1 start-page: 199 year: 2010 end-page: 203 ident: b0530 article-title: Allosteric IGF-1R Inhibitors publication-title: ACS Med. Chem. Lett. – volume: 111 start-page: 143 year: 1990 end-page: 152 ident: b0680 article-title: Molecular characterization of CDC42, a Saccharomyces cerevisiae gene involved in the development of cell polarity publication-title: J. Cell Biol. – volume: 62 start-page: 5749 year: 2002 end-page: 5754 ident: b0490 article-title: ZD1839 (Iressa): an orally active inhibitor of epidermal growth factor signaling with potential for cancer therapy publication-title: Cancer Res. – volume: 34 start-page: D668 year: 2006 end-page: D672 ident: b0020 article-title: DrugBank: a comprehensive resource for in silico drug discovery and exploration publication-title: Nucleic Acids Res. – volume: 503 start-page: 548 year: 2013 end-page: 551 ident: b0320 article-title: K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions publication-title: Nature – volume: 52 start-page: 492 year: 2019 end-page: 500 ident: b0005 article-title: Allosteric Methods and Their Applications: Facilitating the Discovery of Allosteric Drugs and the Investigation of Allosteric Mechanisms publication-title: Acc. Chem. Res. – year: 2021 ident: b0365 article-title: KRAS is vulnerable to reversible switch-II pocket engagement in cells publication-title: bioRxiv – reference: R. Janssen, Development LLC. First-in-Human Study of JNJ-74699157 in Participants With Tumors Harboring the KRAS G12C Mutation, 2020. – volume: 8 start-page: 61 year: 2017 end-page: 66 ident: b0400 article-title: Covalent Guanosine Mimetic Inhibitors of G12C KRAS publication-title: ACS Med. Chem. Lett. – volume: 23 start-page: 1779 year: 2013 end-page: 1785 ident: b0550 article-title: Structure-based discovery of cellular-active allosteric inhibitors of FAK publication-title: Bioorg. Med. Chem. Lett. – volume: 8 start-page: 599 year: 2013 end-page: 607 ident: b0475 article-title: Affinity profiling of the cellular kinome for the nucleotide cofactors ATP, ADP, and GTP publication-title: ACS Chem. Biol. – volume: 5 start-page: 394 year: 2009 end-page: 396 ident: b0545 article-title: A new screening assay for allosteric inhibitors of cSrc publication-title: Nat. Chem. Biol. – ident: 10.1016/j.jmb.2022.167626_b0135 – volume: 12 start-page: 1925 year: 2013 ident: 10.1016/j.jmb.2022.167626_b0710 article-title: RAC1: an emerging therapeutic option for targeting cancer angiogenesis and metastasis publication-title: Mol. Cancer Ther. doi: 10.1158/1535-7163.MCT-13-0164 – volume: 5 start-page: 394 year: 2009 ident: 10.1016/j.jmb.2022.167626_b0545 article-title: A new screening assay for allosteric inhibitors of cSrc publication-title: Nat. Chem. Biol. doi: 10.1038/nchembio.162 – volume: 23 start-page: 1779 year: 2013 ident: 10.1016/j.jmb.2022.167626_b0550 article-title: Structure-based discovery of cellular-active allosteric inhibitors of FAK publication-title: Bioorg. Med. Chem. Lett. doi: 10.1016/j.bmcl.2013.01.047 – ident: 10.1016/j.jmb.2022.167626_b0055 – volume: 2 year: 2005 ident: 10.1016/j.jmb.2022.167626_b0755 article-title: Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain publication-title: PLoS Med. – volume: 25 start-page: 454 year: 2018 ident: 10.1016/j.jmb.2022.167626_b0370 article-title: The reactivity-driven biochemical mechanism of covalent KRAS(G12C) inhibitors publication-title: Nat. Struct. Mol. Biol. doi: 10.1038/s41594-018-0061-5 – volume: 13 start-page: 647 year: 2018 ident: 10.1016/j.jmb.2022.167626_b0030 article-title: Dual Allosteric Inhibition of SHP2 Phosphatase publication-title: ACS Chem. Biol. doi: 10.1021/acschembio.7b00980 – volume: 575 start-page: 217 year: 2019 ident: 10.1016/j.jmb.2022.167626_b0350 article-title: The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity publication-title: Nature doi: 10.1038/s41586-019-1694-1 – volume: 24 issue: 1005–16 year: 2017 ident: 10.1016/j.jmb.2022.167626_b0340 article-title: Potent and Selective Covalent Quinazoline Inhibitors of KRAS G12C publication-title: Cell Chem. Biol. – volume: 543 start-page: 733 year: 2017 ident: 10.1016/j.jmb.2022.167626_b0585 article-title: The allosteric inhibitor ABL001 enables dual targeting of BCR-ABL1 publication-title: Nature doi: 10.1038/nature21702 – volume: 411 start-page: 355 year: 2001 ident: 10.1016/j.jmb.2022.167626_b0430 article-title: Oncogenic kinase signalling publication-title: Nature doi: 10.1038/35077225 – volume: 6 year: 2013 ident: 10.1016/j.jmb.2022.167626_b0775 article-title: Disrupting the scaffold to improve focal adhesion kinase-targeted cancer therapeutics publication-title: Sci. Signal doi: 10.1126/scisignal.2004021 – volume: 108 start-page: 6056 year: 2011 ident: 10.1016/j.jmb.2022.167626_b0610 article-title: Turning a protein kinase on or off from a single allosteric site via disulfide trapping publication-title: Proc. Natl. Acad. Sci. U. S. A. doi: 10.1073/pnas.1102376108 – volume: 20 start-page: 839 year: 2021 ident: 10.1016/j.jmb.2022.167626_b0010 article-title: Trends in kinase drug discovery: targets, indications and inhibitor design publication-title: Nat. Rev. Drug Discov. doi: 10.1038/s41573-021-00252-y – volume: 51 start-page: 11 year: 2007 ident: 10.1016/j.jmb.2022.167626_b0160 article-title: Expression, purification, and characterization of human and rat acetyl coenzyme A carboxylase (ACC) isozymes publication-title: Protein Expr. Purif. doi: 10.1016/j.pep.2006.06.005 – ident: 10.1016/j.jmb.2022.167626_b0315 – volume: 2 start-page: 95 year: 2006 ident: 10.1016/j.jmb.2022.167626_b0570 article-title: Allosteric inhibitors of Bcr-abl-dependent cell proliferation publication-title: Nat. Chem. Biol. doi: 10.1038/nchembio760 – volume: 28 start-page: 847 year: 2021 ident: 10.1016/j.jmb.2022.167626_b0245 article-title: A structural model of a Ras-Raf signalosome publication-title: Nat. Struct. Mol. Biol. doi: 10.1038/s41594-021-00667-6 – year: 1998 ident: 10.1016/j.jmb.2022.167626_b0505 article-title: Preparation of 2-phenylaminobenzoic acids and its amides as MEK inhibitors for treating or preventing septic shock publication-title: Warner Lambert Co. – volume: 39 start-page: 311 year: 1967 ident: 10.1016/j.jmb.2022.167626_b0185 article-title: Morphologic Responses to a Murine Erythroblastosis Virus<xref ref-type=“fn” rid=“FN1”>2</xref> publication-title: JNCI: J. Natl. Cancer Inst. – volume: 90 start-page: 3691 year: 1997 ident: 10.1016/j.jmb.2022.167626_b0495 article-title: The tyrosine kinase inhibitor CGP57148B selectively inhibits the growth of BCR-ABL-positive cells publication-title: Blood doi: 10.1182/blood.V90.9.3691 – volume: 534 start-page: 129 year: 2016 ident: 10.1016/j.jmb.2022.167626_b0525 article-title: Overcoming EGFR (T790M) and EGFR (C797S) resistance with mutant-selective allosteric inhibitors publication-title: Nature doi: 10.1038/nature17960 – volume: 287 start-page: 13228 year: 2012 ident: 10.1016/j.jmb.2022.167626_b0720 article-title: Characterization of EHop-016, novel small molecule inhibitor of Rac GTPase publication-title: J. Biol. Chem. doi: 10.1074/jbc.M111.334524 – volume: 36 start-page: 841 year: 2018 ident: 10.1016/j.jmb.2022.167626_b0750 article-title: Osimertinib as first-line treatment of EGFR mutation-positive advanced non-small-cell lung cancer publication-title: J. Clin. Oncol. doi: 10.1200/JCO.2017.74.7576 – volume: 18 start-page: 2936 year: 2012 ident: 10.1016/j.jmb.2022.167626_b0485 article-title: New directions in targeting protein kinases: focusing upon true allosteric and bivalent inhibitors publication-title: Curr. Pharm. Des. doi: 10.2174/138161212800672813 – volume: 37 start-page: 15631 year: 1998 ident: 10.1016/j.jmb.2022.167626_b0380 article-title: Interaction of a novel GDP exchange inhibitor with the Ras protein publication-title: Biochemistry doi: 10.1021/bi9805691 – volume: 62 start-page: 5749 year: 2002 ident: 10.1016/j.jmb.2022.167626_b0490 article-title: ZD1839 (Iressa): an orally active inhibitor of epidermal growth factor signaling with potential for cancer therapy publication-title: Cancer Res. – volume: 49 start-page: 1779 year: 2017 ident: 10.1016/j.jmb.2022.167626_b0670 article-title: Computational correction of copy number effect improves specificity of CRISPR-Cas9 essentiality screens in cancer cells publication-title: Nat. Genet. doi: 10.1038/ng.3984 – volume: 294 start-page: 13964 year: 2019 ident: 10.1016/j.jmb.2022.167626_b0215 article-title: Structural basis of the atypical activation mechanism of KRAS(V14I) publication-title: J. Biol. Chem. doi: 10.1074/jbc.RA119.009131 – volume: 61 start-page: 203 year: 1990 ident: 10.1016/j.jmb.2022.167626_b0420 article-title: Signal transduction by receptors with tyrosine kinase activity publication-title: Cell doi: 10.1016/0092-8674(90)90801-K – volume: 111 start-page: 143 year: 1990 ident: 10.1016/j.jmb.2022.167626_b0680 article-title: Molecular characterization of CDC42, a Saccharomyces cerevisiae gene involved in the development of cell polarity publication-title: J. Cell Biol. doi: 10.1083/jcb.111.1.143 – volume: 523 start-page: 111 year: 2015 ident: 10.1016/j.jmb.2022.167626_b0150 article-title: Structures of human phosphofructokinase-1 and atomic basis of cancer-associated mutations publication-title: Nature doi: 10.1038/nature14405 – volume: 117 start-page: 3363 year: 2020 ident: 10.1016/j.jmb.2022.167626_b0415 article-title: The small molecule BI-2852 induces a nonfunctional dimer of KRAS publication-title: Proc. Natl. Acad. Sci. U. S. A. doi: 10.1073/pnas.1918164117 – volume: 2 start-page: 15 year: 2010 ident: 10.1016/j.jmb.2022.167626_b0170 article-title: Acetyl-CoA carboxylase-alpha as a novel target for cancer therapy publication-title: Front Biosci. – volume: 62 start-page: 247 year: 2018 ident: 10.1016/j.jmb.2022.167626_b0520 article-title: Discovery of allosteric, potent, subtype selective, and peripherally restricted TrkA kinase inhibitors publication-title: J. Med. Chem. doi: 10.1021/acs.jmedchem.8b00280 – volume: 116 start-page: 15823 year: 2019 ident: 10.1016/j.jmb.2022.167626_b0410 article-title: Drugging an undruggable pocket on KRAS publication-title: Proc. Natl. Acad. Sci. U. S. A. doi: 10.1073/pnas.1904529116 – volume: 153 start-page: 293 year: 2013 ident: 10.1016/j.jmb.2022.167626_b0075 article-title: Allostery in disease and in drug discovery publication-title: Cell doi: 10.1016/j.cell.2013.03.034 – volume: 62 start-page: 791 year: 2010 ident: 10.1016/j.jmb.2022.167626_b0140 article-title: Regulation of mammalian muscle type 6-phosphofructo-1-kinase and its implication for the control of the metabolism publication-title: IUBMB Life doi: 10.1002/iub.393 – volume: 112 start-page: 845 year: 2003 ident: 10.1016/j.jmb.2022.167626_b0565 article-title: A myristoyl/phosphotyrosine switch regulates c-Abl publication-title: Cell doi: 10.1016/S0092-8674(03)00191-0 – volume: 21 start-page: 313 year: 2021 ident: 10.1016/j.jmb.2022.167626_b0770 article-title: Targeting FAK in anticancer combination therapies publication-title: Nat. Rev. Cancer doi: 10.1038/s41568-021-00340-6 – volume: 175 year: 2022 ident: 10.1016/j.jmb.2022.167626_b0445 article-title: Properties of FDA-approved small molecule protein kinase inhibitors: A 2022 update publication-title: Pharmacol. Res. doi: 10.1016/j.phrs.2021.106037 – volume: 19 start-page: 1240 year: 2009 ident: 10.1016/j.jmb.2022.167626_b0620 article-title: Development of thioquinazolinones, allosteric Chk1 kinase inhibitors publication-title: Bioorg. Med. Chem. Lett. doi: 10.1016/j.bmcl.2008.12.076 – volume: 42 year: 2021 ident: 10.1016/j.jmb.2022.167626_b0115 publication-title: EClinicalMedicine. doi: 10.1016/j.eclinm.2021.101185 – volume: 288 start-page: 8531 year: 2013 ident: 10.1016/j.jmb.2022.167626_b0700 article-title: Characterization of a Cdc42 protein inhibitor and its use as a molecular probe publication-title: J. Biol. Chem. doi: 10.1074/jbc.M112.435941 – volume: 59 start-page: 7773 year: 2016 ident: 10.1016/j.jmb.2022.167626_b0035 article-title: Allosteric Inhibition of SHP2: Identification of a Potent, Selective, and Orally Efficacious Phosphatase Inhibitor publication-title: J. Med. Chem. doi: 10.1021/acs.jmedchem.6b00680 – volume: 57 start-page: 433 year: 2004 ident: 10.1016/j.jmb.2022.167626_b0065 article-title: Is allostery an intrinsic property of all dynamic proteins? publication-title: Proteins: Structure, Function, and Bioinformatics. doi: 10.1002/prot.20232 – volume: 292 start-page: 506 year: 1981 ident: 10.1016/j.jmb.2022.167626_b0195 article-title: The p21 src genes of Harvey and Kirsten sarcoma viruses originate from divergent members of a family of normal vertebrate genes publication-title: Nature doi: 10.1038/292506a0 – volume: 170 issue: 564–76 year: 2017 ident: 10.1016/j.jmb.2022.167626_b0675 article-title: Defining a Cancer Dependency Map publication-title: Cell – volume: 11 start-page: 1192 year: 2004 ident: 10.1016/j.jmb.2022.167626_b0510 article-title: Structures of human MAP kinase kinase 1 (MEK1) and MEK2 describe novel noncompetitive kinase inhibition publication-title: Nat. Struct. Mol. Biol. doi: 10.1038/nsmb859 – volume: 19 start-page: 979 year: 2000 ident: 10.1016/j.jmb.2022.167626_b0605 article-title: Identification of a pocket in the PDK1 kinase domain that interacts with PIF and the C-terminal residues of PKA publication-title: EMBO J. doi: 10.1093/emboj/19.5.979 – volume: 12 year: 2017 ident: 10.1016/j.jmb.2022.167626_b0560 article-title: Insights into the binding mode of MEK type-III inhibitors. A step towards discovering and designing allosteric kinase inhibitors across the human kinome publication-title: PLoS ONE – volume: 56 start-page: 15200 year: 2017 ident: 10.1016/j.jmb.2022.167626_b0645 article-title: Lysine-Targeting Covalent Inhibitors publication-title: Angew. Chem. Int. Ed. Engl. doi: 10.1002/anie.201707630 – volume: 6 start-page: 234 year: 2011 ident: 10.1016/j.jmb.2022.167626_b0625 article-title: Discovery and characterization of non-ATP site inhibitors of the mitogen activated protein (MAP) kinases publication-title: ACS Chem. Biol. doi: 10.1021/cb1002619 – volume: 28 start-page: 917 year: 2019 ident: 10.1016/j.jmb.2022.167626_b0175 article-title: Acetyl-CoA carboxylase (ACC) as a therapeutic target for metabolic syndrome and recent developments in ACC1/2 inhibitors publication-title: Expert Opin. Invest. Drugs doi: 10.1080/13543784.2019.1657825 – ident: 10.1016/j.jmb.2022.167626_b0290 – volume: 12 start-page: 1052 year: 2021 ident: 10.1016/j.jmb.2022.167626_b0155 article-title: Fast acting allosteric phosphofructokinase inhibitors block trypanosome glycolysis and cure acute African trypanosomiasis in mice publication-title: Nat. Commun. doi: 10.1038/s41467-021-21273-6 – volume: 298 start-page: 1912 year: 2002 ident: 10.1016/j.jmb.2022.167626_b0470 article-title: The protein kinase complement of the human genome publication-title: Science doi: 10.1126/science.1075762 – volume: 1 start-page: 31 year: 2000 ident: 10.1016/j.jmb.2022.167626_b0425 article-title: Lipid rafts and signal transduction publication-title: Nat. Rev. Mol. Cell Biol. doi: 10.1038/35036052 – volume: 204 start-page: 1104 year: 1964 ident: 10.1016/j.jmb.2022.167626_b0190 article-title: An Unidentified Virus Which Causes the Rapid Production of Tumours in Mice publication-title: Nature doi: 10.1038/2041104b0 – ident: 10.1016/j.jmb.2022.167626_b0295 – volume: 53 start-page: 199 year: 2014 ident: 10.1016/j.jmb.2022.167626_b0390 article-title: Therapeutic targeting of oncogenic K-Ras by a covalent catalytic site inhibitor publication-title: Angew. Chem. Int. Ed. Engl. doi: 10.1002/anie.201307387 – volume: 109 start-page: 275 year: 2002 ident: 10.1016/j.jmb.2022.167626_b0460 article-title: The conformational plasticity of protein kinases publication-title: Cell doi: 10.1016/S0092-8674(02)00741-9 – volume: 49 start-page: 2617 year: 2020 ident: 10.1016/j.jmb.2022.167626_b0500 article-title: Advances in covalent kinase inhibitors publication-title: Chem. Soc. Rev. doi: 10.1039/C9CS00720B – ident: 10.1016/j.jmb.2022.167626_b0595 – volume: 383 start-page: 1207 year: 2020 ident: 10.1016/j.jmb.2022.167626_b0275 article-title: KRAS(G12C) Inhibition with Sotorasib in Advanced Solid Tumors publication-title: N. Engl. J. Med. doi: 10.1056/NEJMoa1917239 – volume: 11 start-page: 876 year: 2020 ident: 10.1016/j.jmb.2022.167626_b0650 article-title: Covalent inhibitors: a rational approach to drug discovery publication-title: RSC Med. Chem. doi: 10.1039/D0MD00154F – ident: 10.1016/j.jmb.2022.167626_b0480 doi: 10.1146/annurev-biochem-090308-173656 – volume: 13 start-page: 193 year: 2021 ident: 10.1016/j.jmb.2022.167626_b0635 article-title: 10 years into the resurgence of covalent drugs publication-title: Future Med. Chem. doi: 10.4155/fmc-2020-0236 – start-page: 389 year: 1961 ident: 10.1016/j.jmb.2022.167626_b0060 – year: 2021 ident: 10.1016/j.jmb.2022.167626_b0365 article-title: KRAS is vulnerable to reversible switch-II pocket engagement in cells publication-title: bioRxiv – volume: 72 start-page: 2457 year: 2012 ident: 10.1016/j.jmb.2022.167626_b0200 article-title: A comprehensive survey of Ras mutations in cancer publication-title: Cancer Res. doi: 10.1158/0008-5472.CAN-11-2612 – ident: 10.1016/j.jmb.2022.167626_b0310 – volume: 558 start-page: 470 year: 2018 ident: 10.1016/j.jmb.2022.167626_b0165 article-title: Structural basis for regulation of human acetyl-CoA carboxylase publication-title: Nature doi: 10.1038/s41586-018-0201-4 – volume: 6 year: 2011 ident: 10.1016/j.jmb.2022.167626_b0580 article-title: Allosteric interactions between the myristate- and ATP-site of the Abl kinase publication-title: PLoS ONE doi: 10.1371/journal.pone.0015929 – volume: 10 start-page: 148 year: 2019 ident: 10.1016/j.jmb.2022.167626_b0100 article-title: The Central Role of Glucokinase in Glucose Homeostasis: A Perspective 50 Years After Demonstrating the Presence of the Enzyme in Islets of Langerhans publication-title: Front. Physiol. doi: 10.3389/fphys.2019.00148 – ident: 10.1016/j.jmb.2022.167626_b0305 – volume: 463 start-page: 501 year: 2010 ident: 10.1016/j.jmb.2022.167626_b0575 article-title: Targeting Bcr-Abl by combining allosteric with ATP-binding-site inhibitors publication-title: Nature doi: 10.1038/nature08675 – volume: 110 start-page: 1261 year: 2013 ident: 10.1016/j.jmb.2022.167626_b0695 article-title: Small molecule targeting Cdc42-intersectin interaction disrupts Golgi organization and suppresses cell motility publication-title: Proc. Natl. Acad. Sci. U. S. A. doi: 10.1073/pnas.1116051110 – ident: 10.1016/j.jmb.2022.167626_b0590 – year: 2021 ident: 10.1016/j.jmb.2022.167626_b0655 article-title: FDA Approval Summary: Sotorasib for KRAS G12C-Mutated Metastatic NSCLC publication-title: Clin. Cancer Res. – volume: 469 start-page: 421 year: 2015 ident: 10.1016/j.jmb.2022.167626_b0145 article-title: Crystal structure of human platelet phosphofructokinase-1 locked in an activated conformation publication-title: Biochem. J. doi: 10.1042/BJ20150251 – volume: 26 start-page: 894 year: 2015 ident: 10.1016/j.jmb.2022.167626_b0265 article-title: A randomized phase II study of the MEK1/MEK2 inhibitor trametinib (GSK1120212) compared with docetaxel in KRAS-mutant advanced non-small-cell lung cancer (NSCLC)dagger publication-title: Ann. Oncol. doi: 10.1093/annonc/mdv072 – volume: 6 start-page: 316 year: 2016 ident: 10.1016/j.jmb.2022.167626_b0335 article-title: Selective Inhibition of Oncogenic KRAS Output with Small Molecules Targeting the Inactive State publication-title: Cancer Discov. doi: 10.1158/2159-8290.CD-15-1105 – volume: 34 start-page: D668 year: 2006 ident: 10.1016/j.jmb.2022.167626_b0020 article-title: DrugBank: a comprehensive resource for in silico drug discovery and exploration publication-title: Nucleic Acids Res. doi: 10.1093/nar/gkj067 – volume: 1796 start-page: 91 year: 2009 ident: 10.1016/j.jmb.2022.167626_b0730 article-title: Rho GTPase function in tumorigenesis publication-title: Biochim. Biophys. Acta, Mol. Cell. Biol. Lipids – volume: 5 start-page: 817 year: 1997 ident: 10.1016/j.jmb.2022.167626_b0375 article-title: Detection and structural characterization of ras oncoprotein-inhibitors complexes by electrospray mass spectrometry publication-title: Bioorg. Med. Chem. doi: 10.1016/S0968-0896(97)00021-7 – volume: 13 start-page: 773 year: 2012 ident: 10.1016/j.jmb.2022.167626_b0270 article-title: Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial publication-title: Lancet Oncol. doi: 10.1016/S1470-2045(12)70270-X – volume: 51 start-page: 6140 year: 2012 ident: 10.1016/j.jmb.2022.167626_b0405 article-title: Discovery of small molecules that bind to K-Ras and inhibit Sos-mediated activation publication-title: Angew. Chem. Int. Ed. Engl. doi: 10.1002/anie.201201358 – volume: 16 start-page: 327 year: 1991 ident: 10.1016/j.jmb.2022.167626_b0250 article-title: Affinity of guanine nucleotide binding proteins for their ligands: facts and artefacts publication-title: Trends Biochem. Sci. doi: 10.1016/0968-0004(91)90134-H – volume: 97 year: 2019 ident: 10.1016/j.jmb.2022.167626_b0050 article-title: Drug hunters explore allostery’s advantages publication-title: Chem. & Eng. News – start-page: 1 year: 2019 ident: 10.1016/j.jmb.2022.167626_b0070 article-title: Allostery in Drug Development – volume: 19 start-page: 699 year: 2012 ident: 10.1016/j.jmb.2022.167626_b0735 article-title: Rational design of small molecule inhibitors targeting RhoA subfamily Rho GTPases publication-title: Chem. Biol. doi: 10.1016/j.chembiol.2012.05.009 – volume: 118 start-page: 4014 year: 2012 ident: 10.1016/j.jmb.2022.167626_b0740 article-title: NRAS mutation status is an independent prognostic factor in metastatic melanoma publication-title: Cancer-Am Cancer Soc. – volume: 115 start-page: 1702 year: 2015 ident: 10.1016/j.jmb.2022.167626_b0090 article-title: New look at hemoglobin allostery publication-title: Chem. Rev. doi: 10.1021/cr500495x – volume: 9 start-page: 738 year: 2019 ident: 10.1016/j.jmb.2022.167626_b0210 article-title: Tissue-Specific Oncogenic Activity of KRAS(A146T) publication-title: Cancer Discov. doi: 10.1158/2159-8290.CD-18-1220 – volume: 155 issue: 1463–73 year: 2018 ident: 10.1016/j.jmb.2022.167626_b0180 article-title: GS-0976 Reduces Hepatic Steatosis and Fibrosis Markers in Patients With Nonalcoholic Fatty Liver Disease publication-title: Gastroenterology – volume: 5 start-page: 125 year: 1997 ident: 10.1016/j.jmb.2022.167626_b0385 article-title: Ras oncoprotein inhibitors: the discovery of potent, ras nucleotide exchange inhibitors and the structural determination of a drug-protein complex publication-title: Bioorg. Med. Chem. doi: 10.1016/S0968-0896(96)00202-7 – volume: 12 start-page: 429 year: 2004 ident: 10.1016/j.jmb.2022.167626_b0095 article-title: Structural basis for allosteric regulation of the monomeric allosteric enzyme human glucokinase publication-title: Structure. doi: 10.1016/j.str.2004.02.005 – volume: 375 start-page: 554 year: 1995 ident: 10.1016/j.jmb.2022.167626_b0360 article-title: The 2.2 Å crystal structure of the Ras-binding domain of the serine/threonine kinase c-Raf1 in complex with RaplA and a GTP analogue publication-title: Nature doi: 10.1038/375554a0 – volume: 535 start-page: 148 year: 2016 ident: 10.1016/j.jmb.2022.167626_b0040 article-title: Allosteric inhibition of SHP2 phosphatase inhibits cancers driven by receptor tyrosine kinases publication-title: Nature doi: 10.1038/nature18621 – volume: 57 start-page: 324 year: 2018 ident: 10.1016/j.jmb.2022.167626_b0240 article-title: KRAS Switch Mutants D33E and A59G Crystallize in the State 1 Conformation publication-title: Biochemistry doi: 10.1021/acs.biochem.7b00974 – volume: 1 start-page: 199 year: 2010 ident: 10.1016/j.jmb.2022.167626_b0530 article-title: Allosteric IGF-1R Inhibitors publication-title: ACS Med. Chem. Lett. doi: 10.1021/ml100044h – volume: 351 start-page: 604 year: 2016 ident: 10.1016/j.jmb.2022.167626_b0330 article-title: Allele-specific inhibitors inactivate mutant KRAS G12C by a trapping mechanism publication-title: Science doi: 10.1126/science.aad6204 – volume: 9 start-page: 2535 year: 2018 ident: 10.1016/j.jmb.2022.167626_b0760 article-title: Molecular basis of Tousled-Like Kinase 2 activation publication-title: Nat. Commun. doi: 10.1038/s41467-018-04941-y – volume: 6 start-page: 53 year: 2015 ident: 10.1016/j.jmb.2022.167626_b0535 article-title: Discovery of a type III inhibitor of LIM kinase 2 that binds in a DFG-out conformation publication-title: ACS Med. Chem. Lett. doi: 10.1021/ml500242y – volume: 8 start-page: 61 year: 2017 ident: 10.1016/j.jmb.2022.167626_b0400 article-title: Covalent Guanosine Mimetic Inhibitors of G12C KRAS publication-title: ACS Med. Chem. Lett. doi: 10.1021/acsmedchemlett.6b00373 – year: 2021 ident: 10.1016/j.jmb.2022.167626_b0080 article-title: Along the allostery stream: Recent advances in computational methods for allosteric drug discovery publication-title: WIREs Comput. Mol. Sci. – volume: 101 start-page: 7618 year: 2004 ident: 10.1016/j.jmb.2022.167626_b0715 article-title: Rational design and characterization of a Rac GTPase-specific small molecule inhibitor publication-title: Proc. Natl. Acad. Sci. U. S. A. doi: 10.1073/pnas.0307512101 – volume: 9 start-page: 690 year: 2008 ident: 10.1016/j.jmb.2022.167626_b0705 article-title: Mammalian Rho GTPases: new insights into their functions from in vivo studies publication-title: Nat. Rev. Mol. Cell Biol. doi: 10.1038/nrm2476 – volume: 247 start-page: 939 year: 1990 ident: 10.1016/j.jmb.2022.167626_b0205 article-title: Molecular switch for signal transduction: structural differences between active and inactive forms of protooncogenic ras proteins publication-title: Science doi: 10.1126/science.2406906 – ident: 10.1016/j.jmb.2022.167626_b0125 – volume: 112 start-page: 708 year: 2020 ident: 10.1016/j.jmb.2022.167626_b0235 article-title: GTP hydrolysis is modulated by Arg34 in the RASopathy-associated KRAS(P34R) publication-title: Birth Defects Res. doi: 10.1002/bdr2.1647 – volume: 111 start-page: 18590 year: 2014 ident: 10.1016/j.jmb.2022.167626_b0615 article-title: A small-molecule mimic of a peptide docking motif inhibits the protein kinase PDK1 publication-title: Proc. Natl. Acad. Sci. U. S. A. doi: 10.1073/pnas.1415365112 – volume: 17 start-page: 1263 year: 2013 ident: 10.1016/j.jmb.2022.167626_b0685 article-title: Targeting Cdc42 in cancer publication-title: Expert Opin. Ther. Targets. doi: 10.1517/14728222.2013.828037 – volume: 172 start-page: 2675 year: 2015 ident: 10.1016/j.jmb.2022.167626_b0435 article-title: Ten things you should know about protein kinases: IUPHAR R eview 14 publication-title: Br. J. Pharmacol. doi: 10.1111/bph.13096 – volume: 20 start-page: 146 year: 2013 ident: 10.1016/j.jmb.2022.167626_b0745 article-title: Developing irreversible inhibitors of the protein kinase cysteinome publication-title: Chem. Biol. doi: 10.1016/j.chembiol.2012.12.006 – volume: 503 start-page: 548 year: 2013 ident: 10.1016/j.jmb.2022.167626_b0320 article-title: K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions publication-title: Nature doi: 10.1038/nature12796 – volume: 62 start-page: 539 year: 1990 ident: 10.1016/j.jmb.2022.167626_b0230 article-title: Three-dimensional structures of H-ras p21 mutants: molecular basis for their inability to function as signal switch molecules publication-title: Cell doi: 10.1016/0092-8674(90)90018-A – volume: 69 start-page: 373 year: 2000 ident: 10.1016/j.jmb.2022.167626_b0465 article-title: Protein tyrosine kinase structure and function publication-title: Annu. Rev. Biochem. doi: 10.1146/annurev.biochem.69.1.373 – volume: 14 start-page: 889 year: 2019 ident: 10.1016/j.jmb.2022.167626_b0640 article-title: Covalent Inhibition in Drug Discovery publication-title: ChemMedChem doi: 10.1002/cmdc.201900107 – volume: 277 start-page: 333 year: 1997 ident: 10.1016/j.jmb.2022.167626_b0225 article-title: The Ras-RasGAP complex: structural basis for GTPase activation and its loss in oncogenic Ras mutants publication-title: Science doi: 10.1126/science.277.5324.333 – volume: 273 start-page: 20685 year: 1998 ident: 10.1016/j.jmb.2022.167626_b0725 publication-title: Rho GTPases. J Biol Chem. doi: 10.1074/jbc.273.33.20685 – volume: 5 start-page: 572 year: 2015 ident: 10.1016/j.jmb.2022.167626_b0220 article-title: Structural dataset for the fast-exchanging KRAS G13D publication-title: Data Brief. doi: 10.1016/j.dib.2015.10.001 – volume: 2 start-page: 39 year: 2006 ident: 10.1016/j.jmb.2022.167626_b0690 article-title: Secramine inhibits Cdc42-dependent functions in cells and Cdc42 activation in vitro publication-title: Nat. Chem. Biol. doi: 10.1038/nchembio751 – volume: 16 start-page: S751 year: 2021 ident: 10.1016/j.jmb.2022.167626_b0280 article-title: KRYSTAL-1: Activity and preliminary pharmacodynamic (PD) analysis of adagrasib (MRTX849) in patients (Pts) with advanced non-small cell lung cancer (NSCLC) harboring KRASG12C mutation publication-title: J. Thoracic Oncol. doi: 10.1016/S1556-0864(21)01941-9 – volume: 577 start-page: 706 year: 2020 ident: 10.1016/j.jmb.2022.167626_b0665 article-title: Improved protein structure prediction using potentials from deep learning publication-title: Nature doi: 10.1038/s41586-019-1923-7 – volume: 76 start-page: 3827 year: 2019 ident: 10.1016/j.jmb.2022.167626_b0765 article-title: The Tousled-like kinases regulate genome and epigenome stability: implications in development and disease publication-title: Cell. Mol. Life Sci. doi: 10.1007/s00018-019-03208-z – volume: 301 start-page: 370 year: 2003 ident: 10.1016/j.jmb.2022.167626_b0120 article-title: Allosteric activators of glucokinase: potential role in diabetes therapy publication-title: Science doi: 10.1126/science.1084073 – ident: 10.1016/j.jmb.2022.167626_b0600 – volume: 52 start-page: 492 year: 2019 ident: 10.1016/j.jmb.2022.167626_b0005 article-title: Allosteric Methods and Their Applications: Facilitating the Discovery of Allosteric Drugs and the Investigation of Allosteric Mechanisms publication-title: Acc. Chem. Res. doi: 10.1021/acs.accounts.8b00570 – ident: 10.1016/j.jmb.2022.167626_b0300 – volume: 172 issue: 857–68 year: 2018 ident: 10.1016/j.jmb.2022.167626_b0355 article-title: KRAS Dimerization Impacts MEK Inhibitor Sensitivity and Oncogenic Activity of Mutant KRAS publication-title: Cell – ident: 10.1016/j.jmb.2022.167626_b0130 – volume: 172 issue: 578–89 year: 2018 ident: 10.1016/j.jmb.2022.167626_b0345 article-title: Targeting KRAS Mutant Cancers with a Covalent G12C-Specific Inhibitor publication-title: Cell – year: 2021 ident: 10.1016/j.jmb.2022.167626_b0450 article-title: A resource for exploring the understudied human kinome for research and therapeutic opportunities publication-title: bioRxiv – ident: 10.1016/j.jmb.2022.167626_b0285 – volume: 6 start-page: 776 year: 2015 ident: 10.1016/j.jmb.2022.167626_b0555 article-title: Optimization of a dibenzodiazepine hit to a potent and selective allosteric PAK1 inhibitor publication-title: ACS Med. Chem. Lett. doi: 10.1021/acsmedchemlett.5b00102 – volume: 508 start-page: 331 year: 2014 ident: 10.1016/j.jmb.2022.167626_b0015 article-title: The ensemble nature of allostery publication-title: Nature doi: 10.1038/nature13001 – volume: 53 start-page: 357 year: 2010 ident: 10.1016/j.jmb.2022.167626_b0540 article-title: Displacement assay for the detection of stabilizers of inactive kinase conformations publication-title: J. Med. Chem. doi: 10.1021/jm901297e – volume: 19 start-page: 533 year: 2020 ident: 10.1016/j.jmb.2022.167626_b0025 article-title: RAS-targeted therapies: is the undruggable drugged? publication-title: Nat. Rev. Drug Discov. doi: 10.1038/s41573-020-0068-6 – volume: 20 start-page: 2113 year: 2018 ident: 10.1016/j.jmb.2022.167626_b0105 article-title: Dorzagliatin (HMS5552), a novel dual-acting glucokinase activator, improves glycaemic control and pancreatic beta-cell function in patients with type 2 diabetes: A 28-day treatment study using biomarker-guided patient selection publication-title: Diabetes Obes. Metab. doi: 10.1111/dom.13338 – volume: 22 start-page: 73 year: 2011 ident: 10.1016/j.jmb.2022.167626_b0110 article-title: Design, synthesis and biological evaluation of novel glucokinase activators publication-title: Chin. Chem. Lett. doi: 10.1016/j.cclet.2010.07.023 – volume: 3 start-page: 2581 year: 1984 ident: 10.1016/j.jmb.2022.167626_b0255 article-title: Harvey murine sarcoma virus p21 ras protein: biological and biochemical significance of the cysteine nearest the carboxy terminus publication-title: EMBO J. doi: 10.1002/j.1460-2075.1984.tb02177.x – volume: 111 start-page: 8895 year: 2014 ident: 10.1016/j.jmb.2022.167626_b0395 article-title: In situ selectivity profiling and crystal structure of SML-8-73-1, an active site inhibitor of oncogenic K-Ras G12C publication-title: Proc. Natl. Acad. Sci. U. S. A. doi: 10.1073/pnas.1404639111 – volume: 55 start-page: 5291 year: 2012 ident: 10.1016/j.jmb.2022.167626_b0515 article-title: Discovery and optimization of a series of 3-(3-Phenyl-3 H-imidazo [4, 5-b] pyridin-2-yl) pyridin-2-amines: orally bioavailable, selective, and potent ATP-independent Akt inhibitors publication-title: J. Med. Chem. doi: 10.1021/jm300276x – volume: 13 start-page: 1325 year: 2015 ident: 10.1016/j.jmb.2022.167626_b0325 article-title: Biochemical and Structural Analysis of Common Cancer-Associated KRAS Mutations publication-title: Mol. Cancer Res. doi: 10.1158/1541-7786.MCR-15-0203 – volume: 8 start-page: 599 year: 2013 ident: 10.1016/j.jmb.2022.167626_b0475 article-title: Affinity profiling of the cellular kinome for the nucleotide cofactors ATP, ADP, and GTP publication-title: ACS Chem. Biol. doi: 10.1021/cb3005879 – volume: 272 start-page: 14459 year: 1997 ident: 10.1016/j.jmb.2022.167626_b0260 article-title: K- and N-Ras are geranylgeranylated in cells treated with farnesyl protein transferase inhibitors publication-title: J. Biol. Chem. doi: 10.1074/jbc.272.22.14459 – volume: 59 start-page: 13764 year: 2020 ident: 10.1016/j.jmb.2022.167626_b0045 article-title: New Promise and Opportunities for Allosteric Kinase Inhibitors publication-title: Angew. Chem. Int. Ed. Engl. doi: 10.1002/anie.201914525 – volume: 12 start-page: 1889 year: 2012 ident: 10.1016/j.jmb.2022.167626_b0455 article-title: New insights in protein kinase conformational dynamics publication-title: Curr. Top. Med. Chem. doi: 10.2174/156802612804547407 – volume: 228 start-page: 726 year: 1970 ident: 10.1016/j.jmb.2022.167626_b0085 article-title: Stereochemistry of cooperative effects in haemoglobin publication-title: Nature doi: 10.1038/228726a0 – volume: 17 start-page: 413 year: 2022 ident: 10.1016/j.jmb.2022.167626_b0630 article-title: Electrophilic warheads in covalent drug discovery: an overview publication-title: Expert Opin. Drug Discov. doi: 10.1080/17460441.2022.2034783 – volume: 25 start-page: 272 year: 2014 ident: 10.1016/j.jmb.2022.167626_b0440 article-title: Dragging ras back in the ring publication-title: Cancer Cell doi: 10.1016/j.ccr.2014.02.017 |
| SSID | ssj0005348 |
| Score | 2.4382079 |
| SecondaryResourceType | review_article |
| Snippet | [Display omitted]
•Allosteric inhibitors have many theoretical advantages including superior selectivity, the ability to modulate allosteric biological... Allosteric mechanisms are pervasive in nature, but human-designed allosteric perturbagens are rare. The history of KRAS inhibitor development suggests that... Allosteric mechanisms are pervasive in nature, but human-designed allosteric perturbagens are rare. The history of KRASG12C inhibitor development suggests that... Allosteric mechanisms are pervasive in nature, but human-designed allosteric perturbagens are rare. The history of KRASᴳ¹²C inhibitor development suggests that... Allosteric mechanisms are pervasive in nature, but human-designed allosteric perturbagens are rare. The history of KRAS G12C inhibitor development suggests... |
| SourceID | pubmedcentral proquest pubmed crossref elsevier |
| SourceType | Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 167626 |
| SubjectTerms | allosteric inhibitor cancer therapy chemistry covalent inhibitor cysteine cysteinome drug development drugs humans kinase inhibitor KRAS inhibitor ligands molecular biology |
| Title | Therapeutic Targeting the Allosteric Cysteinome of RAS and Kinase Families |
| URI | https://dx.doi.org/10.1016/j.jmb.2022.167626 https://www.ncbi.nlm.nih.gov/pubmed/35595166 https://www.proquest.com/docview/2667786499 https://www.proquest.com/docview/2718234741 https://pubmed.ncbi.nlm.nih.gov/PMC9590303 |
| Volume | 434 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1NTxsxEB0hEGoviNJSAhS5EqdKC9nsrGMfo4goTUQOJUjcLO_GFovCJoLkwIXfzsx-pKRVc-gxiVfZjJ15z-s3bwDOk1Altqk0MbcwCVBzmxeV-CBJCUtiR5hWGJhej2T_Fgd38d0WdOtaGJZVVrm_zOlFtq7euayieTnPMq7x5acXlIBZZ0DIyRXs2OZVfvH6TuYRoaodw3l0fbJZaLweHhPaIrZaF6GkpCD_hU1_c88_JZTvMKm3D3sVmRSd8n4_wZbLD2C3bC_5cgAfunU3t88wGP8utBLjQv5NoCWI_onOdMqVHpQQRZd9nbN89ujEzItfnRth84kYZjlhnSh6ZNDG-gvc9q7G3X5Q9VEIUlS4CJyU3scSicugl8q6aKK0c45PRK1G7dtNh5Kt65RuorcutBOr7UT5yFJ4MTqE7XyWuyMQIcvAPG1BCPzQeqvDVCtaBx4xSpM0bECzjqBJK5Nx7nUxNbWa7MFQ0A0H3ZRBb8CP1SXz0mFj02Csp8WsLRNDCLDpsu_1FBqKO5-J2NzNls-G-Ak76NG-b8MYwu9WhMS9GvC1nPbVnRJdI44q6RvaawtiNYDtu9c_ybP7wsZbx5oybHT8fz_pBD7yK5auhPEpbC-elu4b8aNFclb8Ac5gp_Nz2B-9AXxkDdc |
| linkProvider | Elsevier |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1LT-MwEB6xIAQXxGuX8jQSJ6RA00yMfawqUHkeoEjcLCe1tUElRbvlsJf97czkUSiIHrgmjpKMnfk-x5-_AThIQpXYptLE3MIkQM1lXlTigyQlLIkdYVphYHp9I7v3ePEQP8xAp94Lw7LKKveXOb3I1tWR4yqax89Zxnt8-e8FJWDWGRBy_oA5pM-Xyxgc_X-n84hQ1Zbh3Lxe2ixEXo9PCc0RW62jUFJWkF-B02fy-VFD-Q6UzpZhqWKTol0-8ArMuHwV5sv6kv9WYaFTl3Nbg4ve204r0Sv034RagvifaA8GvNWDMqLosLFzlg-fnBh6cdu-Ezbvi8ssJ7ATRZEMmlmvw_3Zaa_TDapCCkGKCkeBk9L7WCKRGfRSWRf1lXbO8ZKo1aj9SdOhZO86pZvorQtt32rbVz6yFF-MfsJsPszdBoiQdWCe5iCEfmi91WGqFQ0EjxilSRo2oFlH0KSVyzgXuxiYWk72aCjohoNuyqA34HB8yXNpsTGtMdbdYibGiSEImHbZft2FhuLOiyI2d8OXv4YIClvo0cRvShsC8FaERL4a8Kvs9vGTEl8jkirpDicTA2LcgP27J8_k2e_Cx1vHmlJstPm9V9qDhW7v-spcnd9cbsEin2EdSxhvw-zoz4vbIbI0SnaLj-EVhl4PZQ |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Therapeutic+Targeting+the+Allosteric+Cysteinome+of+RAS+and+Kinase+Families&rft.jtitle=Journal+of+molecular+biology&rft.au=Li%2C+Lianbo&rft.au=Meyer%2C+Cynthia&rft.au=Zhou%2C+Zhi-Wei&rft.au=Elmezayen%2C+Ammar&rft.date=2022-09-15&rft.pub=Elsevier+Ltd&rft.issn=0022-2836&rft.volume=434&rft.issue=17&rft_id=info:doi/10.1016%2Fj.jmb.2022.167626&rft.externalDocID=S0022283622002066 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0022-2836&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0022-2836&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0022-2836&client=summon |